Quick viewing(Text Mode)

Expresión En Procesos Neuroinflamatorios Y Neurodegenerativos

Expresión En Procesos Neuroinflamatorios Y Neurodegenerativos

FOSFODIESTERASAS DEL AMPc Y DEL GMPc EN EL CEREBRO: EXPRESIÓN EN PROCESOS NEUROINFLAMATORIOS Y NEURODEGENERATIVOS

Elisabet Reyes Irisarri Barcelona 2007

Bibliografía

171

172 Bibliografía 't Hart BA, Amor S, and Jonker M. 2004. Andersson PB, Perry VH, and Gordon S. 1992. Evaluating the validity of animal models for The acute inflammatory response to research into therapies for immune-based lipopolysaccharide in CNS parenchyma differs disorders. Drug Discovery Today 9:517-524. from that in other body tissues. Neuroscience Abbott NJ and Romero IA. 1996. Transporting 48:169-186. therapeutics across the blood-brain barrier. Andjelkovic AV, Nikolic B, Pachter JS, and Mol Med Today 2:106-113. Zecevic N. 1998. Macrophages/microglial cells Abdel-Latif AA. 2001. Cross talk between cyclic in human central nervous system during nucleotides and polyphosphoinositide development: an immunohistochemical study. hydrolysis, protein kinases, and contraction in Brain Res 814:13-25. smooth muscle. Exp Biol Med 226:153-163. Andoh T, Chock PB, and Chiueh CC. 2002. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Preconditioning-mediated neuroprotection: role Ruppelt A, Mustelin T, Zaccolo M, Houslay M, of nitric oxide, cGMP, and new protein and Tasken K. 2004. TCR- and CD28- expression. Ann N Y Acad Sci 962:1-7. mediated recruitment of 4 Andreeva SG, Dikkes P, Epstein PM, and to lipid rafts potentiates TCR signaling. J Rosenberg PA. 2001. Expression of cGMP- Immunol 173:4847-4858. specific phosphodiesterase 9A mRNA in the Adachi H, Kakiki M, and Kishi Y. 2005. Effects of a rat brain. J Neurosci 21:9068-9076. inhibitor, olprinone, on Angelov DN, Walther M, Streppel M, Guntinas- rhythmical change in tension of human Lichius O, and Neiss WF. 1998. The cerebral gastroepiploic artery. Eur J Pharmacol perivascular cells. Adv Anat Embryol Cell Biol 528:137-143. 147:1-87. Ahmed T and Frey JU. 2003. Expression of the Archelos JJ, Jung S, Maurer M, Schmied M, specific type IV phosphodiesterase gene Lassmann H, Tamatani T, Miyasaka M, Toyka PDE4B3 during different phases of long-term KV, and Hartung HP. 1993. Inhibition of potentiation in single hippocampal slices of experimental autoimmune encephalomyelitis rats in vitro. Neuroscience 117:627-638. by an antibody to the intercellular adhesion Airaksinen E, Larsson M, Lundberg I, and Forsell molecule ICAM-1. Ann Neurol 34:145-154. Y. 2004. Cognitive functions in depressive Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand disorders: evidence from a population-based C, Pruniaux MP, Jin SL, and Conti M. 2004. study. Psychol Med 34:83-91. Nonredundant function of Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch 4D and 4B in neutrophil recruitment to the site B, Jacobson R, Ryan T, and Davis KL. 1996. A of inflammation. J Immunol 173:7531-7538. pilot study of prednisone in Alzheimer's Arp J, Kirchhof MG, Baroja ML, Nazarian SH, disease. Dementia 7:201-206. Chau TA, Strathdee CA, Ball EH, and Akasaka S, Nomura M, Nishii H, Fujimoto N, Ueta Madrenas J. 2003. Regulation of T-cell Y, Tsutsui M, Shimokawa H, Yanagihara N, activation by phosphodiesterase 4B2 requires and Matsumoto T. 2006. The hypothalamo- its dynamic redistribution during immunological pituitary axis responses to lipopolysaccharide- synapse formation. Mol Cell Biol 23:8042- induced endotoxemia in mice lacking inducible 8057. nitric oxide synthase. Brain Res 1089:1-9. ASHMAN DF, PRICE TD, MELICOW MM, and Akwa Y, Hassett DE, Eloranta ML, Sandberg K, LIPTON R. 1963. Isolation of Adenosine 3,5- Masliah E, Powell H, Whitton JL, Bloom FE, Monophosphate and Guanosine 3,5- and Campbell IL. 1998. Transgenic expression Monophosphate from Rat Urine. Biochemical of IFN-alpha in the central nervous system of and Biophysical Research Communications mice protects against lethal neurotropic viral 11:330-&. infection but induces inflammation and Asirvatham AL, Galligan SG, Schillace RV, Davey neurodegeneration. J Immunol 161:5016- MP, Vasta V, Beavo JA, and Carr DW. 2004. 5026. A-kinase anchoring proteins interact with Albert PR, Sajedi N, Lemonde S, and Ghahremani phosphodiesterases in T lymphocyte cell lines. MH. 1999. Constitutive G(i2)-dependent J Immunol 173:4806-4814. activation of adenylyl cyclase type II by the 5- Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih HT1A receptor. Inhibition by anxiolytic partial R, Mansuy I, Hawkins RD, and Kandel ER. agonists. J Biol Chem 274:35469-35474. 1999. Age-related defects in spatial memory Alexander SPH, Mathie A, and Peters JA. 2004. are correlated with defects in the late phase of Guide to receptors and channels, 1st edition. hippocampal long-term potentiation in vitro and British Journal of Pharmacology 141:S1-S126. are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U Altmann DM and Boyton RJ. 2004. Models of S A 96:5280-5285. multiple sclerosis. Drug Discovery Today 1:405-410. Baecker PA, Obernolte R, Bach C, Yee C, and Shelton ER. 1994. Isolation of a cDNA Alvarez R, Sette C, Yang D, Eglen RM, Wilhelm encoding a human -sensitive cyclic R, Shelton ER, and Conti M. 1995. Activation AMP phosphodiesterase (PDE IVD). Gene and selective inhibition of a cyclic AMP- 138:253-256. specific phosphodiesterase, PDE-4D3. Mol Pharmacol 48:616-622. Baillie GS and Houslay MD. 2005. Arrestin times for compartmentalised cAMP signalling and

173 Bibliografía phosphodiesterase-4 . Curr Opin Cell Morgan T, Picken CL, and Watson RJ. 2001. Biol 17:129-134. Synthesis and structure-activity relationships Baillie GS, Huston E, Scotland G, Hodgkin M, Gall of guanine analogues as phosphodiesterase 7 I, Peden AH, MacKenzie C, Houslay ES, (PDE7) inhibitors. Bioorg Med Chem Lett Currie R, Pettitt TR, Walmsley AR, Wakelam 11:1081-1083. MJ, Warwicker J, and Houslay MD. 2002. Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, TAPAS-1, a novel microdomain within the and Madrenas J. 1999. Specific CD3 epsilon unique N-terminal region of the PDE4A1 association of a phosphodiesterase 4B isoform cAMP-specific phosphodiesterase that allows determines its selective tyrosine rapid, Ca2+-triggered membrane association phosphorylation after CD3 ligation. J Immunol with selectivity for interaction with phosphatidic 162:2016-2023. acid. J Biol Chem 277:28298-28309. Basu A, Krady JK, and Levison SW. 2004. Baillie GS, MacKenzie SJ, McPhee I, and Houslay Interleukin-1: a master regulator of MD. 2000. Sub-family selective actions in the neuroinflammation. J Neurosci Res 78:151- ability of Erk2 MAP kinase to phosphorylate 156. and regulate the activity of PDE4 cyclic AMP- Baumer W, Hoppmann J, Rundfeldt C, and specific phosphodiesterases. Br J Pharmacol Kietzmann M. 2007. Highly selective 131:811-819. phosphodiesterase 4 inhibitors for the Baillie GS, Scott JD, and Houslay MD. 2005. treatment of allergic skin diseases and Compartmentalisation of phosphodiesterases psoriasis. Inflamm Allergy Drug Targets 6:17- and protein kinase A: opposites attract. FEBS 26. Lett 579:3264-3270. Bazan NG, Colangelo V, and Lukiw WJ. 2002. Bajetto A, Bonavia R, Barbero S, Florio T, and Prostaglandins and other lipid mediators in Schettini G. 2001. Chemokines and their Alzheimer's disease. Prostaglandins Other receptors in the central nervous system. Front Lipid Mediat 68-69:197-210. Neuroendocrinol 22:147-184. Beard MB, O'Connell JC, Bolger GB, and Houslay Bajetto A, Bonavia R, Barbero S, and Schettini G. MD. 1999. The unique N-terminal domain of 2002. Characterization of chemokines and the cAMP phosphodiesterase PDE4D4 allows their receptors in the central nervous system: for interaction with specific SH3 domains. physiopathological implications. J Neurochem FEBS Lett 460:173-177. 82:1311-1329. Beard MB, Olsen AE, Jones RE, Erdogan S, Bal-Price A and Brown GC. 2001. Inflammatory Houslay MD, and Bolger GB. 2000. UCR1 and neurodegeneration mediated by nitric oxide UCR2 domains unique to the cAMP-specific from activated glia-inhibiting neuronal phosphodiesterase family form a discrete respiration, causing glutamate release and module via electrostatic interactions. J Biol excitotoxicity. J Neurosci 21:6480-6491. Chem 275:10349-10358. Ballerini P, Di Iorio P, Ciccarelli R, Nargi E, Beavo JA. 1995a. cGMP inhibition of heart D'Alimonte I, Traversa U, Rathbone MP, and phosphodiesterase: is it clinically relevant? Caciagli F. 2002. Glial cells express multiple [editorial; comment]. J Clin Invest 95:445. ATP binding cassette proteins which are Beavo JA. 1995b. Cyclic nucleotide involved in ATP release. Neuroreport 13:1789- phosphodiesterases: functional implications of 1792. multiple isoforms. Physiol Rev 75:725-748. Baltrons MA, Pifarre P, Ferrer I, Carot JM, and Beavo JA and Brunton LL. 2002. Cyclic nucleotide Garcia A. 2004. Reduced expression of NO- research -- still expanding after half a century. sensitive guanylyl cyclase in reactive Nat Rev Mol Cell Biol 3:710-718. astrocytes of Alzheimer disease, Creutzfeldt- Jakob disease, and multiple sclerosis brains. Beavo JA, Conti M, and Heaslip RJ. 1994. Neurobiol Dis 17:462-472. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46:399-405. Barad M, Bourtchouladze R, Winder DG, Golan H, and Kandel E. 1998. Rolipram, a type IV- Beavo JA, Hardman JG, and Sutherland EW. specific phosphodiesterase inhibitor, facilitates 1971. Stimulation of adenosine 3',5'- the establishment of long-lasting long-term monophosphate hydrolysis by guanosine 3',5'- potentiation and improves memory. Proc Natl monophosphate. J Biol Chem 246:3841-3846. Acad Sci U S A 95:15020-15025. Beavo JA and Reifsnyder DH. 1990. Primary Baranano DE, Ferris CD, and Snyder SH. 2001. sequence of cyclic nucleotide Atypical neural messengers. Trends Neurosci phosphodiesterase isozymes and the design 24:99-106. of selective inhibitors. Trends Pharmacol Sci 11:150-155. Barnes AP, Livera G, Huang P, Sun C, O'Neal WK, Conti M, Stutts MJ, and Milgram SL. Behn D and Potter MJ. 2001. -mediated 2005. Phosphodiesterase 4D forms a cAMP reduction in retinal function in heterozygous diffusion barrier at the apical membrane of the mice lacking the gamma-subunit of airway epithelium. J Biol Chem 280:7997- phosphodiesterase. Invest Ophthalmol Vis Sci 8003. 42:523-527. Barnes MJ, Cooper N, Davenport RJ, Dyke HJ, Bender AT and Beavo JA. 2006. Cyclic nucleotide Galleway FP, Galvin FC, Gowers L, Haughan phosphodiesterases: molecular regulation to AF, Lowe C, Meissner JW, Montana JG, clinical use. Pharmacol Rev 58:488-520.

174 Bibliografía Berrendero F, Sanchez A, Cabranes A, Puerta C, R, and Wachtel H. 1988. Is phosphodiesterase Ramos JA, Garcia-Merino A, and Fernandez- inhibition a new mechanism of antidepressant Ruiz J. 2001. Changes in cannabinoid CB(1) action? A double blind double-dummy study receptors in striatal and cortical regions of rats between rolipram and desipramine in with experimental allergic encephalomyelitis, hospitalized major and/or endogenous an animal model of multiple sclerosis. Synapse depressives. Eur Arch Psychiatry Neurol Sci 41:195-202. 238:2-6. BERTHET J, RALL TW, and Sutherland EW. Boess FG, Hendrix M, van der Staay FJ, Erb C, 1957. The relationship of epinephrine and Schreiber R, van Staveren W, de Vente J, glucagon to liver phosphorylase. IV. Effect of Prickaerts J, Blokland A, and Koenig G. 2004. epinephrine and glucagon on the reactivation Inhibition of increases of phosphorylase in liver homogenates. J Biol neuronal cGMP, synaptic plasticity and Chem 224:463-475. memory performance. Neuropharmacology Bertolino A, Crippa D, di Dio S, Fichte K, Musmeci 47:1081-1092. G, Porro V, Rapisarda V, Sastre, and Boguski MS and McCormick F. 1993. Proteins Schratzer M. 1988. Rolipram versus regulating Ras and its relatives. Nature imipramine in inpatients with major, "minor" or 366:643-654. atypical depressive disorder: a double-blind Bolger G, Michaeli T, Martins T, St.John T, Steiner double-dummy study aimed at testing a novel B, Rodgers L, Riggs M, Wigler M, and therapeutic approach. Int Clin Ferguson K. 1993. A family of human Psychopharmacol 3:245-253. phosphodiesterases homologous to the dunce Biber K, Sauter A, Brouwer N, Copray SC, and learning and memory gene product of Boddeke HW. 2001. Ischemia-induced Drosophila melanogaster are potential targets neuronal expression of the microglia attracting for antidepressant drugs. Mol Cell Biol chemokine Secondary Lymphoid-tissue 13:6558-6571. Chemokine (SLC). Glia 34:121-133. Bolger GB, Erdogan S, Jones RE, Loughney K, Bielekova B, Lincoln A, McFarland H, and Martin Scotland G, Hoffmann R, Wilkinson I, Farrell R. 2000. Therapeutic potential of C, and Houslay MD. 1997. Characterization of phosphodiesterase-4 and -3 inhibitors in Th1- five different proteins produced by alternatively mediated autoimmune diseases. J Immunol spliced mRNAs from the human cAMP-specific 164:1117-1124. phosphodiesterase PDE4D gene. Biochem J Bigazzi PE. 1995. Animal models of multiple 328 ( Pt 2):539-548. sclerosis. Clin Immunol Immunopathol 77:3. Bolger GB, McCahill A, Huston E, Cheung YF, Blease K, Burke-Gaffney A, and Hellewell PG. McSorley T, Baillie GS, and Houslay MD. 1998. Modulation of cell adhesion molecule 2003. The unique amino-terminal region of the expression and function on human lung PDE4D5 cAMP phosphodiesterase isoform microvascular endothelial cells by inhibition of confers preferential interaction with beta- phosphodiesterases 3 and 4. Br J Pharmacol arrestins. J Biol Chem 278:49230-49238. 124:229-237. Bolger GB, Rodgers L, and Riggs M. 1994. Bliss TV and Gardner-Medwin AR. 1973. Long- Differential CNS expression of alternative lasting potentiation of synaptic transmission in mRNA isoforms of the mammalian genes the dentate area of the unanaestetized rabbit encoding cAMP-specific phosphodiesterases. following stimulation of the perforant path. J Gene 149:237-244. Physiol 232:357-374. Bonkale WL, Cowburn RF, Ohm TG, Bogdanovic Bliss TV and Lomo T. 1973. Long-lasting N, and Fastbom J. 1999. A quantitative potentiation of synaptic transmission in the autoradiographic study of [3H]cAMP binding to dentate area of the anaesthetized rabbit cytosolic and particulate protein kinase A in following stimulation of the perforant path. J post-mortem brain staged for Alzheimer's Physiol 232:331-356. disease neurofibrillary changes and amyloid deposits. Brain Res 818:383-396. Blokland A, Schreiber R, and Prickaerts J. 2006. Improving memory: a role for Bonkale WL, Winblad B, Ravid R, and Cowburn phosphodiesterases. Curr Pharm Des RF. 1995. Reduced nitric oxide responsive 12:2511-2523. soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's Bloom TJ and Beavo JA. 1996. Identification and disease. Neurosci Lett 187:5-8. tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Acad Sci U S A 93:14188-14192. Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C. 1996. Sildenafil: an orally active Blumer KJ and Johnson GL. 1994. Diversity in type 5 cyclic GMP-specific phosphodiesterase function and regulation of MAP kinase inhibitor for the treatment of penile erectile pathways. Trends Biochem Sci 19:236-240. dysfunction. Int J Impot Res 8:47-52. Blusztajn JK and Berse B. 2000. The cholinergic Borinson H.L. and Wang SC. 1953. Physiology neuronal phenotype in Alzheimer's disease. and pharmacology of vomiting. Pharmacol Rev Metab Brain Dis 15:45-64. 5:193-230. Bobon D, Breulet M, Gerard-Vandenhove MA, Borrelli E, Montmayeur JP, Foulkes NS, and Guiot-Goffioul F, Plomteux G, Sastre, Sassone-Corsi P. 1992. Signal transduction Schratzer M, Troisfontaines B, von Frenckell

175 Bibliografía and gene control: the cAMP pathway. Crit Rev Burns F, Zhao AZ, and Beavo JA. 1996. Cyclic Oncog 3:321-338. nucleotide phosphodiesterases: gene Borst P and Elferink RO. 2002. Mammalian ABC complexity, regulation by phosphorylation, and transporters in health and disease. Annual physiological implications. Adv Pharmacol Review of Biochemistry 71:537-592. 36:29-48. Bouron A and Reuter H. 1999. The D1 dopamine Butcher RW and Sutherland EW. 1962. receptor agonist SKF-38393 stimulates the Adenosine 3',5'-Phosphate in Biological release of glutamate in the hippocampus. Materials. J Biol Chem 237:1244-1250. Neuroscience 94:1063-1070. Byers D, Davis RL, and Kiger JAJ. 1981. Defect in Braak H and Braak E. 1991. Neuropathological cyclic AMP phosphodiesterase due to the stageing of Alzheimer-related changes. Acta dunce mutation of learning in Drosophila Neuropathol (Berl) 82:239-259. melanogaster. Nature 289:79-81. Braak H and Braak E. 1997. Frequency of stages Cali JJ, Parekh RS, and Krupinski J. 1996. Splice of Alzheimer-related lesions in different age variants of type VIII adenylyl cyclase. categories. Neurobiol Aging 18:351-357. Differences in glycosylation and regulation by Ca2+/calmodulin. J Biol Chem 271:1089-1095. Braak H, Braak E, Bohl J, and Bratzke H. 1998. Evolution of Alzheimer's disease related Campbell IL. 2005. Cytokine-mediated cortical lesions. J Neural Transm Suppl 54:97- inflammation, tumorigenesis, and disease- 106. associated JAK/STAT/SOCS signaling circuits in the CNS. Brain Res Brain Res Rev 48:166- Bradley J, Zhang YN, Bakin R, Lester HA, Ronnett 177. GV, and Zinn K. 1997. Functional expression of the heteromeric ''olfactory'' cyclic nucleotide- Campbell IL and Powell HC. 1996. Role of gated channel in the hippocampus: A potential Cytokines in Demyelinating Disease Studied in effector of synaptic plasticity in brain neurons. Transgenic Mice. Methods 10:462-477. Journal of Neuroscience 17:1993-2005. Cannella B, Cross AH, and Raine CS. 1991. Brandon EP, Idzerda RL, and McKnight GS. 1997. Adhesion-related molecules in the central PKA isoforms, neural pathways, and nervous system. Upregulation correlates with behaviour: making the connection. Curr Opin inflammatory cell influx during relapsing Neurobiol 7:397-403. experimental autoimmune encephalomyelitis. Lab Invest 65:23-31. Braun T and Dods RF. 1975. Development of A Mn2+-Sensitive, Soluble Adenylate Cyclase in Cano E and Mahadevan LC. 1995. Parallel signal Rat Testis. Proceedings of the National processing among mammalian MAPKs. Academy of Sciences of the United States of Trends Biochem Sci 20:117-122. America 72:1097-1101. Cao C, Matsumura K, Yamagata K, and Breder CD, Hazuka C, Ghayur T, Klug C, Huginin Watanabe Y. 1997. Involvement of M, Yasuda K, Teng M, and Saper CB. 1994. cyclooxygenase-2 in LPS-induced fever and Regional induction of tumor necrosis factor regulation of its mRNA by LPS in the rat brain. alpha expression in the mouse brain after Am J Physiol 272:R1712-R1725. systemic lipopolysaccharide administration. Card GL, Blasdel L, England BP, Zhang C, Suzuki Proc Natl Acad Sci U S A 91:11393-11397. Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bredt DS and Snyder SH. 1989. Nitric oxide Bollag G, Milburn MV, Kim SH, Schlessinger J, mediates glutamate-linked enhancement of and Zhang KY. 2005. A family of cGMP levels in the cerebellum. Proc Natl Acad phosphodiesterase inhibitors discovered by Sci U S A 86:9030-9033. cocrystallography and scaffold-based drug design. Nat Biotechnol 23:201-207. Brenner S, Prosch S, Schenke-Layland K, Riese U, Gausmann U, and Platzer C. 2003. cAMP- Carpenter DO, Briggs DB, Knox AP, and induced Interleukin-10 promoter activation Strominger N. 1988. Excitation of area depends on CCAAT/enhancer-binding protein postrema neurons by transmitters, peptides, expression and monocytic differentiation. J and cyclic nucleotides. J Neurophysiol 59:358- Biol Chem 278:5597-5604. 369. Broadwell RD and Salcman M. 1981. Expanding Carson MJ. 2002. Microglia as liaisons between the definition of the blood-brain barrier to the immune and central nervous systems: protein. Proc Natl Acad Sci U S A 78:7820- functional implications for multiple sclerosis. 7824. Glia 40:218-231. Brown TH, Chapman PF, Kairiss EW, and Keenan Carson MJ, Reilly CR, Sutcliffe JG, and Lo D. CL. 1988. Long-term synaptic potentiation. 1998. Mature microglia resemble immature Science 242:724-728. antigen-presenting cells. Glia 22:72-85. Brown TH and Zador AM. 1990. Hippocampus. In Castro A, Abasolo MI, Gil C, Segarra V, and Gordon M.Shepherd, editor. The Synaptic Martínez A. 2001. CoMFA of benzyl Organization of the Brain. New York: Oxford derivatives of 2,1,3-benzo and University Press. p 346-388. benzothieno[3,2-alpha]thiadiazine 2,2- dioxides: clues for the design of Burgunder JM and Cheung PT. 1994. Expression phosphodiesterase 7 inhibitors. Eur J Med of Soluble Guanylyl Cyclase Gene in Adult-Rat Chem 36:333-338. Brain. European Journal of Neuroscience 6:211-217. Castro A, Jerez MJ, Gil C, and Martinez A. 2005. Cyclic nucleotide phosphodiesterases and

176 Bibliografía their role in immunomodulatory responses: reinforcement, movement, and affect. J Comp advances in the development of specific Neurol 407:287-301. phosphodiesterase inhibitors. Med Res Rev Chiang CS, Powell HC, Gold LH, Samimi A, and 25:229-244. Campbell IL. 1996. Macrophage/microglial- Cellerino A, Bahr M, and Isenmann S. 2000. mediated primary demyelination and motor Apoptosis in the developing visual system. Cell disease induced by the central nervous system and Tissue Research 301:53-69. production of interleukin-3 in transgenic mice. Chang BY, Conroy KB, Machleder EM, and J Clin Invest 97:1512-1524. Cartwright CA. 1998. RACK1, a receptor for Choi YH, Ekholm D, Krall J, Ahmad F, Degerman activated C kinase and a homolog of the beta E, Manganiello VC, and Movsesian MA. 2001. subunit of G proteins, inhibits activity of src Identification of a novel isoform of the cyclic- tyrosine kinases and growth of NIH 3T3 cells. nucleotide phosphodiesterase PDE3A Mol Cell Biol 18:3245-3256. expressed in vascular smooth-muscle Chang BY, Harte RA, and Cartwright CA. 2002. myocytes. Biochem J 353:41-50. RACK1: a novel substrate for the Src protein- Ciani E, Guidi S, Bartesaghi R, and Contestabile tyrosine kinase. Oncogene 21:7619-7629. A. 2002. Nitric oxide regulates cGMP- Charbonneau H, Prusti RK, LeTrong H, dependent cAMP-responsive element binding Sonnenburg WK, Mullaney PJ, Walsh KA, and protein phosphorylation and Bcl-2 expression Beavo JA. 1990. Identification of a noncatalytic in cerebellar neurons: implication for a survival cGMP-binding domain conserved in both the role of nitric oxide. J Neurochem 82:1282- cGMP-stimulated and photoreceptor cyclic 1289. nucleotide phosphodiesterases. Proc Natl Cirillo MA and Seidman LJ. 2003. Verbal Acad Sci U S A 87:288-292. declarative memory dysfunction in Chelmickaschorr E, Kwasniewski MN, Thomas schizophrenia: from clinical assessment to BE, and Arnason BGW. 1989. The Beta- genetics and brain mechanisms. Neuropsychol Adrenergic Agonist Isoproterenol Suppresses Rev 13:43-77. Experimental Allergic Encephalomyelitis in Coimbra R, Melbostad H, Loomis W, Tobar M, Lewis Rats. Journal of Neuroimmunology and Hoyt DB. 2005a. Phosphodiesterase 25:203-207. inhibition decreases nuclear factor-kappaB Chen C and Regehr WG. 1997. The mechanism activation and shifts the cytokine response of cAMP-mediated enhancement at a toward anti-inflammatory activity in acute cerebellar synapse. J Neurosci 17:8687-8694. endotoxemia. J Trauma 59:575-582. Chen HW, Jiang WS, and Tzeng CR. 2001a. Nitric Coimbra R, Porcides RD, Melbostad H, Loomis oxide as a regulator in preimplantation embryo W, Tobar M, Hoyt DB, and Wolf P. 2005b. development and apoptosis. Fertility and Nonspecific phosphodiesterase inhibition Sterility 75:1163-1171. attenuates liver injury in acute endotoxemia. Surg Infect (Larchmt ) 6:73-85. Chen S, Dell EJ, Lin F, Sai J, and Hamm HE. 2004. RACK1 regulates specific functions of Comery TA, Martone RL, Aschmies S, Atchison Gbetagamma. J Biol Chem 279:17861-17868. KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Chen S, Lin F, and Hamm HE. 2005. RACK1 Jacobsen JS, and Marquis KL. 2005. Acute binds to a signal transfer region of G gamma-secretase inhibition improves betagamma and inhibits C contextual fear conditioning in the Tg2576 beta2 activation. J Biol Chem 280:33445- mouse model of Alzheimer's disease. J 33452. Neurosci 25:8898-8902. Chen Z, Nield HS, Sun H, Barbier A, and Patel Consilvio C, Vincent AM, and Feldman EL. 2004. TB. 1995. Expression of type V adenylyl Neuroinflammation, COX-2, and ALS--a dual cyclase is required for epidermal growth factor- role? Exp Neurol 187:1-10. mediated stimulation of cAMP accumulation. J Biol Chem 270:27525-27530. Conti M. 2000. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Chen ZS, Lee K, and Kruh GD. 2001b. Transport Endocrinol 14:1317-1327. of cyclic nucleotides and estradiol 17-beta-D- glueuronide by multidrug resistance protein 4 - Conti M and Jin SL. 1999. The molecular biology Resistance to 6-mercaptopurine and 6- of cyclic nucleotide phosphodiesterases. Prog thioguanine. Journal of Biological Chemistry Nucleic Acid Res Mol Biol 63:1-38. 276:33747-33754. Conti M, Nemoz G, Sette C, and Vicini E. 1995. Cheng JF and Grande JP. 2007. Cyclic nucleotide Recent progress in understanding the phosphodiesterase (PDE) inhibitors: Novel hormonal regulation of phosphodiesterases. therapeutic agents for progressive renal Endocr Rev 16:370-389. disease. Experimental Biology and Medicine Conti M, Richter W, Mehats C, Livera G, Park JY, 232:38-51. and Jin C. 2003. Cyclic AMP-specific PDE4 Cherfils J and Chardin P. 1999. GEFs: structural phosphodiesterases as critical components of basis for their activation of small GTP-binding cyclic AMP signaling. J Biol Chem 278:5493- proteins. Trends Biochem Sci 24:306-311. 5496. Cherry JA and Davis RL. 1999. Cyclic AMP Cook TA, Ghomashchi F, Gelb MH, Florio SK, and phosphodiesterases are localized in regions of Beavo JA. 2000. Binding of the delta subunit to the mouse brain associated with rod phosphodiesterase catalytic subunits

177 Bibliografía requires methylated, prenylated C-termini of Cummings JL, Donohue JA, and Brooks RL. the catalytic subunits. Biochemistry 39:13516- 2000. The relationship between donepezil and 13523. behavioral disturbances in patients with Cook TA, Ghomashchi F, Gelb MH, Florio SK, and Alzheimer's disease. Am J Geriatr Psychiatry Beavo JA. 2001. The delta subunit of type 6 8:134-140. phosphodiesterase reduces light-induced Cummings JL, Vinters HV, Cole GM, and cGMP hydrolysis in rod outer segments. J Biol Khachaturian ZS. 1998. Alzheimer's disease: Chem 276:5248-5255. etiologies, pathophysiology, cognitive reserve, Cooper DM, Mons N, and Karpen JW. 1995. and treatment opportunities. Neurology 51:S2- Adenylyl cyclases and the interaction between 17. calcium and cAMP signalling. Nature 374:421- D'Amours MR, Granovsky AE, Artemyev NO, and 424. Cote RH. 1999. Potency and mechanism of Coquil JF, Franks DJ, Wells JN, Dupuis M, and action of E4021, a type 5 phosphodiesterase Hamet P. 1980. Characteristics of a new isozyme-selective inhibitor, on the binding protein distinct from the kinase for photoreceptor phosphodiesterase depend on guanosine 3':5'-monophosphate in rat the state of activation of the . Mol platelets. Biochim Biophys Acta 631:148-165. Pharmacol 55:508-514. Corbin JD. 2004. Mechanisms of action of PDE5 D'Andrea MR, Qiu Y, Haynes-Johnson D, inhibition in erectile dysfunction. Int J Impot Bhattacharjee S, Kraft P, and Lundeen S. Res 16 Suppl 1:S4-S7. 2005. Expression of PDE11A in normal and malignant human tissues. J Histochem Corbin JD and Francis SH. 1999. Cyclic GMP Cytochem 53:895-903. phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729-13732. D'Sa C, Tolbert LM, Conti M, and Duman RS. 2002. Regulation of cAMP-specific Corbin JD, Ogreid D, Miller JP, Suva RH, Jastorff phosphodiesterases type 4B and 4D (PDE4) B, and Doskeland SO. 1986. Studies of Cgmp splice variants by cAMP signaling in primary Analog Specificity and Function of the 2 cortical neurons. J Neurochem 81:745-757. Intrasubunit Binding-Sites of Cgmp-Dependent Protein-Kinase. Journal of Biological Dal Canto MC, Melvold RW, Kim BS, and Miller Chemistry 261:1208-1214. SD. 1995. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) Corbin JD, Thomas MK, Wolfe L, Shabb JB, and Theiler's murine encephalomyelitis virus Woodford TA, and Francis SH. 1990. New (TMEV) infection. A pathological and Insights Into Cgmp Action. Advances in immunological comparison. Microsc Res Tech Second Messenger and Phosphoprotein 32:215-229. Research 24:411-418. Dauwalder B and Davis RL. 1995. Conditional Corbin JD, Turko IV, Beasley A, and Francis SH. rescue of the dunce learning/memory and 2000. Phosphorylation of phosphodiesterase-5 female fertility defects with Drosophila or rat by cyclic nucleotide-dependent protein kinase transgenes. J Neurosci 15:3490-3499. alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267:2760-2767. Davis RL. 1996. Physiology and biochemistry of Drosophila learning mutants. Physiol Rev Correale J and Villa A. 2004. The neuroprotective 76:299-317. role of inflammation in nervous system injuries. J Neurol 251:1304-1316. Davis RL, Cherry J, Dauwalder B, Han PL, and Skoulakis E. 1995. The cyclic AMP system Cortés R, Mengod G, Celada P, and Artigas F. and Drosophila learning. Mol Cell Biochem 1993. p-chlorophenylalanine increases 149-150:271-278. tryptophan-5-hydroxylase mRNA levels in the rat dorsal raphe: a time course study using in Davis RL, Takayasu H, Eberwine M, and Myres J. situ hybridization. J Neurochem 60:761-764. 1989. Cloning and characterization of mammalian homologs of the Drosophila Coskran TM, Morton D, Menniti FS, Adamowicz dunce+ gene. Proc Natl Acad Sci U S A WO, Kleiman RJ, Ryan AM, Strick CA, 86:3604-3608. Schmidt CJ, and Stephenson DT. 2006. Immunohistochemical Localization of Davoren PR and Sutherland EW. 1963. Effect of Phosphodiesterase 10A (PDE10A) in Multiple L-Epinephrine and Other Agents on Synthesis Mammalian Species. J Histochem Cytochem. and Release of Adenosine 3',5'-Phosphate by Whole Pigeon Erythrocytes. Journal of Cowburn RF, Fowler CJ, and O'Neill C. 1996. Biological Chemistry 238:3009-&. Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Acta Neurol Scand Suppl 165:25-32. Nijman SM, Wittinghofer A, and Bos JL. 1998. Epac is a Rap1 guanine-nucleotide-exchange Crespo P, Xu N, Simonds WF, and Gutkind JS. factor directly activated by cyclic AMP. Nature 1994. Ras-dependent activation of MAP 396:474-477. kinase pathway mediated by G-protein beta gamma subunits. Nature 369:418-420. de Vente J. 2004. cGMP: a second messenger for acetylcholine in the brain? Neurochem Int Cserr HF and Knopf PM. 1992. Cervical 45:799-812. lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. de Vente J, Hopkins DA, Markerink-Van Ittersum Immunol Today 13:507-512. M, Emson PC, Schmidt HH, and Steinbusch HW. 1998. Distribution of nitric oxide synthase

178 Bibliografía and nitric oxide-receptive, cyclic GMP- Ref Type: Journal (Full) producing structures in the rat brain. Domek-Lopacinska K, van de WM, Markerink-Van Neuroscience 87:207-241. Ittersum M, Steinbusch HW, and de Vente J. de Vente J, Markerink-Van Ittersum M, Axer H, 2005b. Nitric oxide-induced cGMP synthesis in and Steinbusch HW. 2001. Nitric-oxide- the cholinergic system during the development induced cGMP synthesis in cholinergic and aging of the rat brain. Brain Res Dev Brain neurons in the rat brain. Exp Brain Res Res 158:72-81. 136:480-491. Dousa TP. 1999. Cyclic-3',5'-nucleotide Defer N, Best-Belpomme M, and Hanoune J. phosphodiesterase isozymes in cell biology 2000. Tissue specificity and physiological and pathophysiology of the kidney. Kidney Int relevance of various isoforms of adenylyl 55:29-62. cyclase. Am J Physiol Renal 279:F400-F416. Dudai Y, Jan YN, Byers D, Quinn WG, and Degerman E, Belfrage P, and Manganiello VC. Benzer S. 1976. dunce, a mutant of Drosophila 1997. Structure, localization, and regulation of deficient in learning. Proc Natl Acad Sci U S A cGMP-inhibited phosphodiesterase (PDE3). J 73:1684-1688. Biol Chem 272:6823-6826. Dumaz N and Marais R. 2005. Integrating signals Degerman E, Manganiello VC, Newman AH, Rice between cAMP and the RAS/RAF/MEK/ERK KC, and Belfrage P. 1988. Purification, signalling pathways. Based on the anniversary properties and polyclonal antibodies for the prize of the Gesellschaft fur Biochemie und particulate, low Km cAMP phosphodiesterase Molekularbiologie Lecture delivered on 5 July from bovine adipose tissue. Second 2003 at the Special FEBS Meeting in Brussels. Messengers Phosphoproteins 12:171-182. FEBS J 272:3491-3504. Del Maschio A, De Luigi A, Martin-Padura I, Dunkern TR and Hatzelmann A. 2005. The effect Brockhaus M, Bartfai T, Fruscella P, Adorini L, of Sildenafil on human platelet secretory Martino G, Furlan R, De Simoni MG, and function is controlled by a complex interplay Dejana E. 1999. Leukocyte recruitment in the between phosphodiesterases 2, 3 and 5. Cell cerebrospinal fluid of mice with experimental Signal 17:331-339. meningitis is inhibited by an antibody to Duplantier AJ, Biggers MS, Chambers RJ, Cheng junctional adhesion molecule (JAM). J Exp JB, Cooper K, Damon DB, Eggler JF, Kraus Med 190:1351-1356. KG, Marfat A, Masamune H, Pillar JS, Shirley Denninger JW and Marletta MA. 1999. Guanylate JT, Umland JP, and Watson JW. 1996. cyclase and the .NO/cGMP signaling pathway. Biarylcarboxylic acids and -amides: inhibition Biochim Biophys Acta 1411:334-350. of phosphodiesterase type IV versus Dent G and Giembycz MA. 1996. [3H]rolipram binding activity and their Phosphodiesterase inhibitors: Lily the Pink's relationship to emetic behavior in the ferret. J medicinal compound for asthma? Thorax Med Chem 39:120-125. 51:647-649. Duzic E and Lanier SM. 1992. Factors Dietrich JB. 2002. The adhesion molecule ICAM-1 Determining the Specificity of Signal and its regulation in relation with the blood- Transduction by Guanine Nucleotide-Binding brain barrier. J Neuroimmunol 128:58-68. Protein-Coupled Receptors .3. Coupling of Alpha-2-Adrenergic Receptor Subtypes in A Dinter H, Tse J, Halks-Miller M, Asarnow D, Cell Type-Specific Manner. Journal of Onuffer J, Faulds D, Mitrovic B, Kirsch G, Biological Chemistry 267:24045-24052. Laurent H, Esperling P, Seidelmann D, Ottow E, Schneider H, Tuohy VK, Wachtel H, and Dyke HJ and Montana JG. 2002. Update on the Perez HD. 2000. The type IV therapeutic potential of PDE4 inhibitors. Exp phosphodiesterase specific inhibitor Opin Invest Drugs 11:1-13. mesopram inhibits experimental autoimmune Eason MG and Liggett SB. 1995. Identification of encephalomyelitis in rodents. J Neuroimmunol A G(S) Coupling Domain in the Amino- 108:136-146. Terminus of the 3Rd Intracellular Loop of the Dodge KL, Khouangsathiene S, Kapiloff MS, Alpha(2A)-Adrenergic Receptor - Evidence for Mouton R, Hill EV, Houslay MD, Langeberg Distinct Structural Determinants That Confer LK, and Scott JD. 2001. mAKAP assembles a G(S) Versus G(I) Coupling. Journal of protein kinase A/PDE4 phosphodiesterase Biological Chemistry 270:24753-24760. cAMP signaling module. EMBO J 20:1921- Eigler A, Siegmund B, Emmerich U, Baumann KH, 1930. Hartmann G, and Endres S. 1998. Anti- Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle inflammatory activities of cAMP-elevating Michel JJ, Langeberg LK, Kapiloff MS, and agents: enhancement of IL-10 synthesis and Scott JD. 2005. The protein kinase A concurrent suppression of TNF production. J anchoring protein mAKAP coordinates two Leukoc Biol 63:101-107. integrated cAMP effector pathways. Nature El Bawab S, Macovschi O, Sette C, Conti M, 437:574-578. Lagarde M, Nemoz G, and Prigent AF. 1997. Domek-Lopacinska K, Markerink-Van Ittersum M, Selective stimulation of a cAMP-specific Steinbusch HW,de Vente J. 2005a. Changes phosphodiesterase (PDE4A5) isoform by in expression of cGMP selective phosphatidic acid molecular species phosphodiesterases 2, 5 and 9 in the rat brain endogenously formed in rat thymocytes. Eur J during aging. BMC Pharmacol 5 (Suppl 1), 15. Biochem 247:1151-1157.

179 Bibliografía El Husseini AED, Williams J, Reiner PB, Pelech S, history. Prostaglandins Leukot Essent Fatty and Vincent SR. 1999. Localization of the Acids 71:161-169. cGMP-dependent protein kinases in relation to Favot L, Keravis T, and Lugnier C. 2004. nitric oxide synthase in the brain. Journal of Modulation of VEGF-induced endothelial cell Chemical Neuroanatomy 17:45-55. cycle protein expression through cyclic AMP Elmquist JK, Breder CD, Sherin JE, Scammell TE, hydrolysis by PDE2 and PDE4. Thromb Hickey WF, Dewitt D, and Saper CB. 1997. Haemost 92:634-645. Intravenous lipopolysaccharide induces Fawcett L, Baxendale R, Stacey P, McGrouther C, cyclooxygenase 2-like immunoreactivity in rat Harrow I, Soderling S, Hetman J, Beavo JA, brain perivascular microglia and meningeal and Phillips SC. 2000. Molecular cloning and macrophages. J Comp Neurol 381:119-129. characterization of a distinct human Elmquist JK, Scammell TE, Jacobson CD, and phosphodiesterase gene family: PDE11A. Saper CB. 1996. Distribution of Fos-like Proc Natl Acad Sci U S A 97:3702-3707. immunoreactivity in the rat brain following Fearns C, Kravchenko VV, Ulevitch RJ, and intravenous lipopolysaccharide administration. Loskutoff DJ. 1995. Murine CD14 gene J Comp Neurol 371:85-103. expression in vivo: extramyeloid synthesis and Elson G, Dunn-Siegrist I, Daubeuf B, and Pugin J. regulation by lipopolysaccharide. J Exp Med 2007. Contribution of Toll-like receptors to the 181:857-866. innate immune response to Gram-negative Federman AD, Conklin BR, Schrader KA, Reed and Gram-positive bacteria. Blood 109:1574- RR, and Bourne HR. 1992. Hormonal 1583. stimulation of adenylyl cyclase through Gi- Endo H, Sasaki K, Tonosaki A, and Kayama T. protein beta gamma subunits. Nature 356:159- 1998. Three-dimensional and ultrastructural 161. ICAM-1 distribution in the choroid plexus, Fedoroff S, Zhai R, and Novak JP. 1997. Microglia arachnoid membrane and dural sinus of and astroglia have a common progenitor cell. J inflammatory rats induced by LPS injection in Neurosci Res 50:477-486. the lateral ventricles. Brain Res 793:297-301. Fierz W, Endler B, Reske K, Wekerle H, and Engelhardt B, Wolburg-Buchholz K, and Wolburg Fontana A. 1985. Astrocytes as antigen- H. 2001. Involvement of the choroid plexus in presenting cells. I. Induction of Ia antigen central nervous system inflammation. Microsc expression on astrocytes by T cells via Res Tech 52:112-129. immune interferon and its effect on antigen Engels P, Abdel'Al S, Hulley P, and Lubbert H. presentation. J Immunol 134:3785-3793. 1995a. Brain distribution of four rat Fischmeister R, Castro L, Abi-Gerges A, Rochais homologues of the Drosophila dunce cAMP F, and Vandecasteele G. 2005. Species- and phosphodiesterase. J Neurosci Res 41:169- tissue-dependent effects of NO and cyclic 178. GMP on cardiac ion channels. Comp Biochem Engels P, Fichtel K, and Lubbert H. 1994. Physiol A Mol Integr Physiol 142:136-143. Expression and regulation of human and rat Fischmeister R and Mery PF. 1996. [Regulation of phosphodiesterase type IV isogenes. FEBS cardiac calcium current by cGMP/NO route]. C Lett 350:291-295. R Seances Soc Biol Fil 190:181-206. Engels P, Sullivan M, Muller T, and Lubbert H. Fisher DA, Smith JF, Pillar JS, St Denis SH, and 1995b. Molecular cloning and functional Cheng JB. 1998a. Isolation and expression in yeast of a human cAMP- specific characterization of PDE8A, a novel human phosphodiesterase subtype (PDE IV-C). FEBS cAMP-specific phosphodiesterase. Biochem Lett 358:305-310. Biophys Res Commun 246:570-577. Essayan DM. 1999. Cyclic nucleotide Fisher DA, Smith JF, Pillar JS, St Denis SH, and phosphodiesterase (PDE) inhibitors and Cheng JB. 1998b. Isolation and immunomodulation. Biochem Pharmacol characterization of PDE9A, a novel human 57:965-973. cGMP-specific phosphodiesterase. J Biol Estevez AG, Spear N, Thompson JA, Cornwell Chem 273:15559-15564. TL, Radi R, Barbeito L, and Beckman JS. Fitzpatrick JJ, Stier L, Eichorn A, Dlugacz YD, 1998. Nitric oxide-dependent production of O'Connor LJ, Salinas TK, Smith T, and White cGMP supports the survival of rat embryonic MT. 2004. Hospitalized elders: changes in motor neurons cultured with brain-derived functional and mental status. Outcomes neurotrophic factor. J Neurosci 18:3708-3714. Manag 8:52-56. Fallis RJ, Raine CS, and McFarlin DE. 1989. Fleming YM, Frame MC, and Houslay MD. 2004. Chronic relapsing experimental allergic PDE4-regulated cAMP degradation controls encephalomyelitis in SJL mice following the the assembly of integrin-dependent actin adoptive transfer of an epitope-specific T cell adhesion structures and REF52 cell migration. line. J Neuroimmunol 22:93-105. J Cell Sci 117:2377-2388. Farber DB and Tsang SH. 2003. Stationary night Floris S, Blezer EL, Schreibelt G, Dopp E, van der blindness or progressive retinal degeneration Pol SM, Schadee-Eestermans IL, Nicolay K, in mice carrying different alleles of PDE Dijkstra CD, and de Vries HE. 2004. Blood- gamma. Front Biosci 8:s666-s675. brain barrier permeability and monocyte Farooqui AA and Horrocks LA. 2004. Brain infiltration in experimental allergic A2: a perspective on the

180 Bibliografía encephalomyelitis: a quantitative MRI study. Fritz RB and McFarlin DE. 1989. Encephalitogenic Brain 127:616-627. epitopes of myelin basic protein. Chem Forstermann U, Boissel JP, and Kleinert H. 1998. Immunol 46:101-125. Expressional control of the 'constitutive' Fujino M, Funeshima N, Kitazawa Y, Kimura H, isoforms of nitric oxide synthase (NOS I and Amemiya H, Suzuki S, and Li XK. 2003. NOS III). FASEB J 12:773-790. Amelioration of experimental autoimmune Foster DC, Wedel BJ, Robinson SW, and Garbers encephalomyelitis in lewis rats by FTY720 DL. 1999. Mechanisms of regulation and treatment. Journal of Pharmacology and functions of guanylyl cyclases. Rev Physiol Experimental Therapeutics 305:70-77. Biochem Pharmacol 135:1-39. Fujishige K, Kotera J, Michibata H, Yuasa K, Francis SH, Bessay EP, Kotera J, Grimes KA, Liu Takebayashi S, Okumura K, and Omori K. L, Thompson WJ, and Corbin JD. 2002a. 1999a. Cloning and characterization of a novel Phosphorylation of isolated human human phosphodiesterase that hydrolyzes phosphodiesterase-5 regulatory domain both cAMP and cGMP (PDE10A). J Biol Chem induces an apparent conformational change 274:18438-18445. and increases cGMP binding affinity. J Biol Fujishige K, Kotera J, and Omori K. 1999b. Chem 277:47581-47587. Striatum- and testis-specific Francis SH and Corbin JD. 1994. Structure and phosphodiesterase PDE10A isolation and function of cyclic nucleotide-dependent protein characterization of a rat PDE10A [In Process kinases. Annu Rev Physiol 56:237-272. Citation]. Eur J Biochem 266:1118-1127. Francis SH, Lincoln TM, and Corbin JD. 1980. Fujishige K, Kotera J, Yuasa K, and Omori K. Characterization of a novel cGMP binding 2000. The human phosphodiesterase PDE10A protein from rat lung. J Biol Chem 255:620- gene genomic organization and evolutionary 626. relatedness with other PDEs containing GAF domains. Eur J Biochem 267:5943-5951. Francis SH, Noblett BD, Todd BW, Wells JN, and Corbin JD. 1988. Relaxation of Vascular and Furchgott RF and Zawadzki JV. 1980. The Tracheal Smooth-Muscle by Cyclic-Nucleotide obligatory role of endothelial cells in the Analogs That Preferentially Activate Purified relaxation of arterial smooth muscle by Cgmp-Dependent Protein-Kinase. Molecular acetylcholine. Nature 288:373-376. Pharmacology 34:506-517. Furuyama T, Inagaki S, and Takagi H. 1993a. Francis SH, Turko IV, and Corbin JD. 2001. Cyclic Distribution of type II adenylyl cyclase mRNA nucleotide phosphodiesterases: relating in the rat brain. Mol Brain Res 19:165-170. structure and function. Prog Nucleic Acid Res Furuyama T, Inagaki S, and Takagi H. 1993b. Mol Biol 65:1-52. Localizations of Alpha-1-Subunit and Beta-1- Francis SH, Turko IV, and Corbin JD. 2002b. Subunit of Soluble Guanylate-Cyclase in the Cyclic nucleotide phosphodiesterases: relating Rat-Brain. Molecular Brain Research 20:335- structure and function. Prog Nucleic Acid Res 344. Mol Biol 65:1-52. Gal A, Orth U, Baehr W, Schwinger E, and Frazer A. 1997. Pharmacology of antidepressants. Rosenberg T. 1994. Heterozygous missense J Clin Psychopharmacol 17 Suppl 1:2S-18S. mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant Fredriksson R, Lagerstrom MC, Lundin LG, and stationary night blindness. Nat Genet 7:64-68. Schioth HB. 2003. The G-protein-coupled receptors in the human genome form five main Galperin MY, Nikolskaya AN, and Koonin EV. families. Phylogenetic analysis, paralogon 2001. Novel domains of the prokaryotic two- groups, and fingerprints. Mol Pharmacol component signal transduction systems. 63:1256-1272. FEMS Microbiol Lett 203:11-21. Frenette R, Blouin M, Brideau C, Chauret N, Gamanuma M, Yuasa K, Sasaki T, Sakurai N, Ducharme Y, Friesen RW, Hamel P, Jones Kotera J, and Omori K. 2003. Comparison of TR, Laliberte F, Li C, Masson P, McAuliffe M, enzymatic characterization and gene and Girard Y. 2002. Substituted 4-(2,2- organization of cyclic nucleotide diphenylethyl)pyridine-N-oxides as phosphodiesterase 8 family in humans. Cell phosphodiesterase-4 inhibitors: SAR study Signal 15:565-574. directed toward the improvement of Gantner F, Gotz C, Gekeler V, Schudt C, Wendel pharmacokinetic parameters. Bioorg Med A, and Hatzelmann A. 1998. Chem Lett 12:3009-3013. Phosphodiesterase profile of human B Frey U, Huang YY, and Kandel ER. 1993. Effects lymphocytes from normal and atopic donors of cAMP simulate a late stage of LTP in and the effects of PDE inhibition on B cell hippocampal CA1 neurons. Science 260:1661- proliferation. Br J Pharmacol 123:1031-1038. 1664. Garcia-Jimenez A, Cowburn RF, Ohm TG, Friedman WJ, Larkfors L, Ayer-LeLievre C, Bogdanovic N, Winblad B, and Fastbom J. Ebendal T, Olson L, and Persson H. 1990. 1999. Quantitative autoradiography of Regulation of beta-nerve growth factor [3H]forskolin binding sites in post-mortem expression by inflammatory mediators in brain staged for Alzheimer's disease hippocampal cultures. J Neurosci Res 27:374- neurofibrillary changes and amyloid deposits. 382. Brain Res 850:104-117.

181 Bibliografía Gardner C, Robas N, Cawkill D, and Fidock M. autoimmune encephalomyelitis. 2000. Cloning and characterization of the Neuroimmunomodulation 5:166-171. human and mouse PDE7B, a novel cAMP- Glavas NA, Ostenson C, Schaefer JB, Vasta V, specific cyclic nucleotide phosphodiesterase. and Beavo JA. 2001. T cell activation up- Biochem Biophys Res Commun 272:186-192. regulates cyclic nucleotide Garthwaite J. 1991. Glutamate, nitric oxide and phosphodiesterases 8A1 and 7A3. Proc Natl cell-cell signalling in the nervous system. Acad Sci U S A 98:6319-6324. Trends Neurosci 14:60-67. Gong Y, Chang L, Viola KL, Lacor PN, Lambert Garthwaite J. 1995. Neural nitric oxide signalling. MP, Finch CE, Krafft GA, and Klein WL. 2003. Trends Neurosci 18:51-52. Alzheimer's disease-affected brain: presence Garthwaite J and Boulton CL. 1995. Nitric oxide of oligomeric A beta ligands (ADDLs) suggests signaling in the central nervous system. Annu a molecular basis for reversible memory loss. Rev Physiol 57:683-706. Proc Natl Acad Sci U S A 100:10417-10422. Garthwaite J, Garthwaite G, Palmer RM, and Goodwin JS and Ceuppens J. 1983. Regulation of Moncada S. 1989. NMDA receptor activation the Immune-Response by Prostaglandins. induces nitric oxide synthesis from arginine in Journal of Clinical Immunology 3:295-315. rat brain slices. Eur J Pharmacol 172:413-416. Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Gehrmann J, Mies G, Bonnekoh P, Banati R, and Ron Y. 1995. Both anti-CD11a (LFA-1) Iijima T, Kreutzberg GW, and Hossmann KA. and anti-CD11b (MAC-1) therapy delay the 1993. Microglial reaction in the rat cerebral onset and diminish the severity of cortex induced by cortical spreading experimental autoimmune encephalomyelitis. J depression. Brain Pathol 3:11-17. Neuroimmunol 62:153-160. Genain CP, Roberts T, Davis RL, Nguyen MH, Gouault N, Martin-Chouly CA, Lugnier C, Cupif Uccelli A, Faulds D, Li Y, Hedgpeth J, and JF, Tonnelier A, Feger F, Lagente V, and Hauser SL. 1995. Prevention of autoimmune David M. 2004. Solid-phase synthesis and demyelination in non-human primates by a evaluation of libraries of substituted 4,5- cAMP- specific phosphodiesterase inhibitor. dihydropyridazinones as vasodilator agents. J Proc Natl Acad Sci U S A 92:3601-3605. Pharm Pharmacol 56:1029-1037. Gether U. 2000. Uncovering molecular Greenwood J, Wang Y, and Calder VL. 1995. mechanisms involved in activation of G Lymphocyte adhesion and transendothelial protein-coupled receptors. Endocr Rev 21:90- migration in the central nervous system: the 113. role of LFA-1, ICAM-1, VLA-4 and VCAM-1. off. Immunology 86:408-415. Ghersa P, Hooft vH, Whelan J, Cambet Y, Pescini R, and DeLamarter JF. 1994. Inhibition of E- Grigoriadis N, Tselios T, Deraos S, Orologas A, selectin gene transcription through a cAMP- Deraos G, Matsoukas J, Mavromatis L, and dependent protein kinase pathway. J Biol Milonas I. 2005. Animal models of central Chem 269:29129-29137. nervous system immune-mediated diseases: Therapeutic interventions with bioactive Giembycz MA. 2000. Phosphodiesterase 4 peptides and mimetics. Current Medicinal inhibitors and the treatment of asthma: where Chemistry 12:1513-1519. are we now and where do we go from here? Drugs 59:193-212. Gross SS and Wolin MS. 1995. Nitric oxide: pathophysiological mechanisms. Annu Rev Giembycz MA, Corrigan CJ, Seybold J, Newton R, Physiol 57:737-769. and Barnes PJ. 1996. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human Gross-Langenhoff M, Hofbauer K, Weber J, CD4+ and CD8+ T-lymphocytes: role in Schultz A, and Schultz JE. 2006. cAMP is a regulating proliferation and the biosynthesis of ligand for the tandem GAF domain of human interleukin-2. Br J Pharmacol 118:1945-1958. phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. Gilles-Gonzalez MA and Gonzalez G. 2004. J Biol Chem 281:2841-2846. Signal transduction by heme-containing PAS- domain proteins. J Appl Physiol 96:774-783. Gudermann T, Kalkbrenner F, and Schultz G. 1996. Diversity and selectivity of receptor-G Gillespie PG and Beavo JA. 1988. protein interaction. Annu Rev Pharmacol Characterization of a bovine cone Toxicol 36:429-459. photoreceptor phosphodiesterase purified by cyclic GMP-sepharose chromatography. J Biol Guipponi M, Scott HS, Kudoh J, Kawasaki K, Chem 263:8133-8141. Shibuya K, Shintani A, Asakawa S, Chen H, Lalioti MD, Rossier C, Minoshima S, Shimizu Giordano D, De Stefano ME, Citro G, Modica A, N, and Antonarakis SE. 1998. Identification and Giorgi M. 2001. Expression of cGMP- and characterization of a novel cyclic binding cGMP-specific phosphodiesterase nucleotide phosphodiesterase gene (PDE9A) (PDE5) in mouse tissues and cell lines using that maps to 21q22.3: alternative splicing of an antibody against the enzyme amino- mRNA transcripts, genomic structure and terminal domain. Biochim Biophys Acta sequence. Hum Genet 103:386-392. 1539:16-27. Halbrugge M, Friedrich C, Eigenthaler M, Glabinski AR, Tuohy VK, and Ransohoff RM. Schanzenbacher P, and Walter U. 1990. 1998. Expression of chemokines RANTES, Stoichiometric and Reversible Phosphorylation MIP-1alpha and GRO-alpha correlates with of A 46-Kda Protein in Human Platelets in inflammation in acute experimental

182 Bibliografía Response to Cgmp-Elevating and Camp- disease transgenic mice prior to the onset of Elevating Vasodilators. Journal of Biological motor symptoms. Neuroscience 123:967-981. Chemistry 265:3088-3093. Hendrix M. 2005. Selective inhibitors of cGMP Han P, Werber J, Surana M, Fleischer N, and phosphodiesterases as procognitive agents. Michaeli T. 1999. The calcium/calmodulin- BMC Pharmacol 5 (Suppl. I) S5. dependent phosphodiesterase PDE1C down- Hetman JM, Robas N, Baxendale R, Fidock M, regulates glucose-induced insulin secretion. Phillips SC, Soderling SH, and Beavo JA. Journal of Biological Chemistry 274:22337- 2000a. Cloning and characterization of two 22344. splice variants of human phosphodiesterase Han P, Zhu X, and Michaeli T. 1997. Alternative 11A. Proc Natl Acad Sci U S A 97:12891- splicing of the high affinity cAMP-specific 12895. phosphodiesterase (PDE7A) mRNA in human Hetman JM, Soderling SH, Glavas NA, and Beavo skeletal muscle and heart. J Biol Chem JA. 2000b. Cloning and characterization of 272:16152-16157. PDE7B, a cAMP-specific phosphodiesterase. Hanoune J and Defer N. 2001. Regulation and Proc Natl Acad Sci U S A 97:472-476. role of adenylyl cyclase isoforms. Annu Rev Hickey WF. 1999. Leukocyte traffic in the central Pharmacol Toxicol 41:145-174. nervous system: the participants and their Hanoune J, Pouille Y, Tzavara E, Shen T, roles. Semin Immunol 11:125-137. Lipskaya L, Miyamoto N, Suzuki Y, and Defer Hickey WF, Vass K, and Lassmann H. 1992. Bone N. 1997. Adenylyl cyclases: structure, marrow-derived elements in the central regulation and function in an enzyme nervous system: an immunohistochemical and superfamily. Mol Cell Endocrinol 128:179-194. ultrastructural survey of rat chimeras. J Hansen G, Jin S, Umetsu DT, and Conti M. 2000. Neuropathol Exp Neurol 51:246-256. Absence of muscarinic cholinergic airway Hildebrandt JD. 1997. Role of subunit diversity in responses in mice deficient in the cyclic signaling by heterotrimeric G proteins. nucleotide phosphodiesterase PDE4D [In Biochem Pharmacol 54:325-339. Process Citation]. Proc Natl Acad Sci U S A 97:6751-6756. Hirrlinger J, Konig J, and Dringen R. 2002. Expression of mRNAs of multidrug resistance Hardman JG and Sutherland EW. 1969. Guanyl proteins (Mrps) in cultured rat astrocytes, cyclase, an enzyme catalyzing the formation of oligodendrocytes, microglial cells and guanosine 3',5'-monophosphate from neurones. Journal of Neurochemistry 82:716- guanosine trihosphate. J Biol Chem 244:6363- 719. 6370. Hobbs AJ. 1997. Soluble guanylate cyclase: the Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski forgotten sibling. Trends Pharmacol Sci D, McNamara RK, Streit WJ, Salafranca MN, 18:484-491. Adhikari S, Thompson DA, Botti P, Bacon KB, and Feng L. 1998. Role for neuronally derived Hoeper MM. 2005. Drug treatment of pulmonary fractalkine in mediating interactions between arterial hypertension: current and future neurons and CX3CR1-expressing microglia. agents. Drugs 65:1337-1354. Proc Natl Acad Sci U S A 95:10896-10901. Hoffmann R, Abdel'Al S, and Engels P. 1998a. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Differential distribution of rat PDE-7 mRNA in and Beavo JA. 1986. Isolation and embryonic and adult rat brain. Cell Biochem characterization of bovine cardiac muscle Biophys 28:103-113. cGMP-inhibited phosphodiesterase: a receptor Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood for new cardiotonic drugs. Mol Pharmacol SJ, and Houslay MD. 1999. The MAP kinase 29:506-514. ERK2 inhibits the cyclic AMP-specific Hayashi M, Matsushima K, Ohashi H, Tsunoda H, phosphodiesterase HSPDE4D3 by Murase S, Kawarada Y, and Tanaka T. 1998. phosphorylating it at Ser579. EMBO J 18:893- Molecular cloning and characterization of 903. human PDE8B, a novel thyroid- specific Hoffmann R, Wilkinson IR, McCallum JF, Engels isozyme of 3',5'-cyclic nucleotide P, and Houslay MD. 1998b. cAMP-specific phosphodiesterase. Biochem Biophys Res phosphodiesterase HSPDE4D3 mutants which Commun 250:751-756. mimic activation and changes in rolipram Hayashi M, Shimada Y, Nishimura Y, Hama T, inhibition triggered by protein kinase A and Tanaka T. 2002. Genomic organization, phosphorylation of Ser-54: generation of a chromosomal localization, and alternative molecular model. Biochem J 333 ( Pt 1):139- splicing of the human phosphodiesterase 8B 149. gene. Biochem Biophys Res Commun Hong KW, Lee JH, Kim KY, Park SY, and Lee 297:1253-1258. WS. 2006. : Therapeutic potential Haynes L and Yau KW. 1985. Cyclic Gmp- against focal cerebral ischemic damage. Sensitive Conductance in Outer Segment Current Pharmaceutical Design 12:565-573. Membrane of Catfish Cones. Nature 317:61- Hopkins SJ. 2007. Central nervous system 64. recognition of peripheral inflammation: a Hebb AL, Robertson HA, and Denovan-Wright neural, hormonal collaboration. Acta Biomed EM. 2004. Striatal phosphodiesterase mRNA 78 Suppl 1:231-247. and protein levels are reduced in Huntington's Horton YM, Sullivan M, and Houslay MD. 1995. Molecular cloning of a novel splice variant of 183 Bibliografía human type IVA (PDE-IVA) cyclic AMP Huston E, Beard M, McCallum F, Pyne NJ, phosphodiesterase and localization of the Vandenabeele P, Scotland G, and Houslay gene to the p13.2- q12 region of human MD. 2000. The cAMP-specific chromosome 19 [corrected] [published erratum phosphodiesterase PDE4A5 is cleaved appears in Biochem J 1995 Dec 15;312(Pt downstream of its SH3 interaction domain by 3):991]. Biochem J 308 ( Pt 2):683-691. caspase-3. Consequences for altered Houslay MD. 1995. Compartmentalization of cyclic intracellular distribution. J Biol Chem AMP phosphodiesterases, signalling 275:28063-28074. 'crosstalk', desensitization and the Huston E, Lumb S, Russell A, Catterall C, Ross phosphorylation of Gi-2 add cell specific AH, Steele MR, Bolger GB, Perry MJ, Owens personalization to the control of the levels of RJ, and Houslay MD. 1997. Molecular cloning the second messenger cyclic AMP. Adv and transient expression in COS7 cells of a Enzyme Regul 35:303-338. novel human PDE4B cAMP-specific Houslay MD. 1998. Adaptation in cyclic AMP phosphodiesterase, HSPDE4B3. Biochem J signalling processes: a central role for cyclic 328 ( Pt 2):549-558. AMP phosphodiesterases. Semin Cell Dev Biol Huston E, Pooley L, Julien P, Scotland G, 9:161-167. McPhee I, Sullivan M, Bolger G, and Houslay Houslay MD. 2001. PDE4 cAMP-specific MD. 1996. The human cyclic AMP-specific phosphodiesterases. Prog Nucleic Acid Res phosphodiesterase PDE-46 (HSPDE4A4B) Mol Biol 69:249-315. expressed in transfected COS7 cells occurs as both particulate and cytosolic species that Houslay MD and Adams DR. 2003. PDE4 cAMP exhibit distinct kinetics of inhibition by the phosphodiesterases: modular enzymes that antidepressant rolipram. J Biol Chem orchestrate signalling cross-talk, 271:31334-31344. desensitization and compartmentalization. Biochem J 370:1-18. Ibrahim SM, Mix E, Bottcher T, Koczan D, Gold R, Rolfs A, and Thiesen HJ. 2001. Gene Houslay MD and Kolch W. 2000. Cell-type specific expression profiling of the nervous system in integration of cross-talk between extracellular murine experimental autoimmune signal-regulated kinase and cAMP signaling. encephalomyelitis. Brain 124:1927-1938. Mol Pharmacol 58:659-668. Ichimura M and Kase H. 1993. A new cyclic Houslay MD and Milligan G. 1997. Tailoring nucleotide phosphodiesterase isozyme cAMP-signalling responses through isoform expressed in the T- lymphocyte cell lines. multiplicity. Trends Biochem Sci 22:217-224. Biochem Biophys Res Commun 193:985-990. Houslay MD, Schafer P, and Zhang KY. 2005. Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Keynote review: phosphodiesterase-4 as a Chaudhuri G. 1987a. Endothelium-derived therapeutic target. Drug Discov Today relaxing factor produced and released from 10:1503-1519. artery and vein is nitric oxide. Proc Natl Acad Houslay MD, Sullivan M, and Bolger GB. 1998. Sci U S A 84:9265-9269. The multienzyme PDE4 cyclic adenosine Ignarro LJ, Byrns RE, Buga GM, and Wood KS. monophosphate-specific phosphodiesterase 1987b. Endothelium-derived relaxing factor family: intracellular targeting, regulation, and from pulmonary artery and vein possesses selective inhibition by compounds exerting pharmacologic and chemical properties anti-inflammatory and antidepressant actions. identical to those of nitric oxide radical. Circ Adv Pharmacol 44:225-342. Res 61:866-879. Howard KM and Olson MS. 2000. The expression Issazadeh S, Ljungdahl A, Hojeberg B, Mustafa and localization of plasma platelet-activating M, and Olsson T. 1995a. Cytokine production factor acetylhydrolase in endotoxemic rats. J in the central nervous system of Lewis rats Biol Chem 275:19891-19896. with experimental autoimmune Hu H, McCaw EA, Hebb AL, Gomez GT, and encephalomyelitis: dynamics of mRNA Denovan-Wright EM. 2004. Mutant huntingtin expression for interleukin-10, interleukin-12, affects the rate of transcription of striatum- cytolysin, tumor necrosis factor alpha and specific isoforms of phosphodiesterase 10A. tumor necrosis factor beta. J Neuroimmunol Eur J Neurosci 20:3351-3363. 61:205-212. Huai Q, Colicelli J, and Ke H. 2003. The crystal Issazadeh S, Mustafa M, Ljungdahl A, Hojeberg structure of AMP-bound PDE4 suggests a B, Dagerlind A, Elde R, and Olsson T. 1995b. mechanism for phosphodiesterase catalysis. Interferon gamma, interleukin 4 and Biochemistry 42:13220-13226. transforming growth factor beta in Huang Z, Ducharme Y, Macdonald D, and experimental autoimmune encephalomyelitis in Robichaud A. 2001. The next generation of Lewis rats: dynamics of cellular mRNA PDE4 inhibitors. Curr Opin Chem Biol 5:432- expression in the central nervous system and 438. lymphoid cells. J Neurosci Res 40:579-590. Humpl T, Reyes JT, Holtby H, Stephens D, and Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka Adatia I. 2005. Beneficial effect of oral N, Shiku H, and Nakano T. 1996. sildenafil therapy on childhood pulmonary Characterization of the isoenzymes of cyclic arterial hypertension: twelve-month clinical trial nucleotide phosphodiesterase in human of a single-drug, open-label, pilot study. platelets and the effects of E4021. Cell Signal Circulation 111:3274-3280. 8:575-581.

184 Bibliografía Iwahashi Y, Furuyama T, Tano Y, Ishimoto I, Jordan FL and Thomas WE. 1988. Brain Shimomura Y, and Inagaki S. 1996. macrophages: questions of origin and Differential distribution of mRNA encoding interrelationship. Brain Res 472:165-178. cAMP-specific phosphodiesterase isoforms in Jordan JD and Iyengar R. 1998. Modes of the rat brain. Mol Brain Res 38:14-24. interactions between signaling pathways. Iyengar R. 1996. Gating by cyclic AMP: expanded Biochem Pharmacol 55:1347-1352. role for an old signaling pathway. Science Juilfs DM, Fulle HJ, Zhao AZ, Houslay MD, 271:461-463. Garbers DL, and Beavo JA. 1997. A subset of Jacobitz S, McLaughlin MM, Livi GP, Burman M, olfactory neurons that selectively express and Torphy TJ. 1996. Mapping the functional cGMP-stimulated phosphodiesterase (PDE2) domains of human recombinant and guanylyl cyclase-D define a unique phosphodiesterase 4A: structural requirements olfactory signal transduction pathway. Proc for catalytic activity and rolipram binding. Mol Natl Acad Sci U S A 94:3388-3395. Pharmacol 50:891-899. Kajimura N, Yamazaki M, Morikawa K, Yamazaki Jacobitz S, Ryan MD, McLaughlin MM, Livi GP, A, and Mayanagi K. 2002. Three-dimensional DeWolf WEJ, and Torphy TJ. 1997. Role of structure of non-activated cGMP conserved histidines in catalytic activity and phosphodiesterase 6 and comparison of its inhibitor binding of human recombinant image with those of activated forms. J Struct phosphodiesterase 4A. Mol Pharmacol Biol 139:27-38. 51:999-1006. Kakkar R, Raju RV, Rajput AH, and Sharma RK. Janeway CA, Jr. and Medzhitov R. 2002. Innate 1996. Inhibition of bovine brain calmodulin- immune recognition. Annu Rev Immunol dependent cyclic nucleotide 20:197-216. phosphodiesterase isozymes by deprenyl. Life Jarchau T, Hausler C, Markert T, Pohler D, Sci 59:L337-L341. Vandekerckhove J, Dejonge HR, Lohmann Kakkar R, Raju RV, and Sharma RK. 1999. SM, and Walter U. 1994. Cloning, Expression, Calmodulin-dependent cyclic nucleotide and In-Situ Localization of Rat Intestinal phosphodiesterase (PDE1). Cell Mol Life Sci Cgmp-Dependent Protein-Kinase-Ii. 55:1164-1186. Proceedings of the National Academy of Kalyvas A and David S. 2004. Cytosolic Sciences of the United States of America plays a key role in the 91:9426-9430. pathogenesis of multiple sclerosis-like disease. Jedlitschky G, Burchell B, and Keppler D. 2000. Neuron 41:323-335. The multidrug resistance protein 5 functions as Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake an ATP-dependent export pump for cyclic M, and Czerwiec F. 2003. Cilostazol as a nucleotides. Journal of Biological Chemistry unique antithrombotic agent. Curr Pharm Des 275:30069-30074. 9:2289-2302. Jee Y, Liu RL, Bai XF, Campagnolo DI, Shi FD, Kammer GM, Boehm CA, Rudolph SA, and and Vollmer TL. 2006. Do T(h)2 cells mediate Schultz LA. 1988. Mobility of the human T the effects of glatiramer acetate in lymphocyte surface molecules CD3, CD4, and experimental autoimmune encephalomyelitis? CD8: regulation by a cAMP-dependent International Immunology 18:537-544. pathway. Proc Natl Acad Sci U S A 85:792- Jeffery P. 2005. Phosphodiesterase 4-selective 796. inhibition: novel therapy for the inflammation of Kanda N and Watanabe S. 2001. Regulatory roles COPD. Pulm Pharmacol Ther 18:9-17. of adenylate cyclase and cyclic nucleotide Jin SL and Conti M. 2002. Induction of the cyclic phosphodiesterases 1 and 4 in interleukin-13 nucleotide phosphodiesterase PDE4B is production by activated human T cells. essential for LPS-activated TNF-alpha Biochem Pharmacol 62:495-507. responses. Proc Natl Acad Sci U S A 99:7628- Kandel ER and Schwartz JH. 1982. Molecular 7633. biology of learning: modulation of transmitter Jin SL, Lan L, Zoudilova M, and Conti M. 2005a. release. Science 218:433-443. Specific role of phosphodiesterase 4B in Karpus WJ and Ransohoff RM. 1998. Chemokine lipopolysaccharide-induced signaling in mouse regulation of experimental autoimmune macrophages. J Immunol 175:1523-1531. encephalomyelitis: temporal and spatial Jin SL, Latour AM, and Conti M. 2005b. expression patterns govern disease Generation of PDE4 knockout mice by gene pathogenesis. J Immunol 161:2667-2671. targeting. Methods Mol Biol 307:191-210. Kasuya J, Goko H, and Fujita-Yamaguchi Y. 1995. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, and Multiple transcripts for the human cardiac form Conti M. 1999. Impaired growth and fertility of of the cGMP-inhibited cAMP cAMP-specific phosphodiesterase PDE4D- phosphodiesterase. J Biol Chem 270:14305- deficient mice. Proc Natl Acad Sci U S A 14312. 96:11998-12003. Katsuki H and Okuda S. 1995. Arachidonic acid Jin SL, Swinnen JV, and Conti M. 1992. as a neurotoxic and neurotrophic substance. Characterization of the structure of a low Km, Prog Neurobiol 46:607-636. rolipram-sensitive cAMP phosphodiesterase. Kaur C, Hao AJ, Wu CH, and Ling EA. 2001. Mapping of the catalytic domain. J Biol Chem Origin of microglia. Microsc Res Tech 54:2-9. 267:18929-18939.

185 Bibliografía Kawasaki H, Sprihtgett GM, Toki S, Canales JJ, induced apoptosis by cGMP-dependent Harlan P, Blumenstiel JP, Chen EJ, Bany IA, inhibition of caspase signaling. J Neurosci Mochizuki N, Ashbacher A, Matsuda M, 19:6740-6747. Housman DE, and Graybiel AM. 1998a. A Rap Kincaid RL, Balaban CD, and Billingsley ML. guanine nucleotide exchange factor enriched 1992. Regional and developmental expression highly in the basal ganglia. Proceedings of the of calmodulin-dependent cyclic nucleotide National Academy of Sciences of the United phosphodiesterase in rat brain. Adv Second States of America 95:13278-13283. Messenger Phosphoprotein Res 25:111-122. Kawasaki H, Springett GM, Mochizuki N, Toki S, King CD and Mayer SE. 1974. Inhibition of Egress Nakaya M, Matsuda M, Housman DE, and of Adenosine-3',5'-Monophosphate from Graybiel AM. 1998b. A family of cAMP-binding Pigeon Erythrocytes. Molecular Pharmacology proteins that directly activate Rap1. Science 10:941-953. 282:2275-2279. Kingston PA, Zufall F, and Barnstable CJ. 1999. Kelly JJ, Barnes PJ, and Giembycz MA. 1996. Widespread expression of olfactory cyclic Phosphodiesterase 4 in macrophages: nucleotide-gated channel genes in rat brain: relationship between cAMP accumulation, Implications for neuronal signalling. Synapse suppression of cAMP hydrolysis and inhibition 32:1-12. of [3H]R-(- )-rolipram binding by selective inhibitors. Biochem J 318 ( Pt 2):425-436. Klussmann E, Maric K, Wiesner B, Beyermann M, and Rosenthal W. 1999. Protein kinase A Kenan Y, Murata T, Shakur Y, Degerman E, and anchoring proteins are required for Manganiello VC. 2000. Functions of the N- vasopressin-mediated translocation of terminal region of cyclic nucleotide aquaporin-2 into cell membranes of renal phosphodiesterase 3 (PDE 3) isoforms. J Biol principal cells. J Biol Chem 274:4934-4938. Chem 275:12331-12338. Kobayashi Y, Kawai K, Honda H, Tomida S, Niimi Kerschensteiner M, Stadelmann C, Dechant G, N, Tamatani T, Miyasaka M, and Yoshikai Y. Wekerle H, and Hohlfeld R. 2003. 1995. Antibodies against leukocyte function- Neurotrophic cross-talk between the nervous associated antigen-1 and against intercellular and immune systems: implications for adhesion molecule-1 together suppress the neurological diseases. Ann Neurol 53:292-304. progression of experimental allergic Khoury SJ, Hancock WW, and Weiner HL. 1992. encephalomyelitis. Cell Immunol 164:295-305. Oral tolerance to myelin basic protein and Kool M, deHaas M, Scheffer GL, Scheper RJ, natural recovery from experimental vanEijk MJT, Juijn JA, Baas F, and Borst P. autoimmune encephalomyelitis are associated 1997. Analysis of expression of cMOAT with downregulation of inflammatory cytokines (MRP2), MRP3, MRP4, and MRP5, and differential upregulation of transforming homologues of the multidrug resistance- growth factor beta, interleukin 4, and associated protein gene (MRP1), in human prostaglandin E expression in the brain. J Exp cancer cell lines. Cancer Research 57:3537- Med 176:1355-1364. 3547. Kida S, Steart PV, Zhang ET, and Weller RO. Kotera J, Fujishige K, Akatsuka H, Imai Y, Yanaka 1993. Perivascular cells act as scavengers in N, and Omori K. 1998. Novel alternative splice the cerebral perivascular spaces and remain variants of cGMP-binding cGMP-specific distinct from pericytes, microglia and phosphodiesterase. Journal of Biological macrophages. Acta Neuropathol (Berl) 85:646- Chemistry 273:26982-26990. 652. Kotera J, Fujishige K, Imai Y, Kawai E, Michibata Kiemer AK, Hartung T, and Vollmar AM. 2000. H, Akatsuka H, Yanaka N, and Omori K. cGMP-mediated inhibition of TNF-alpha 1999a. Genomic origin and transcriptional production by the atrial natriuretic peptide in regulation of two variants of cGMP-binding murine macrophages. J Immunol 165:175-181. cGMP-specific phosphodiesterases. Eur J Kiemer AK and Vollmar AM. 1998. Autocrine Biochem 262:866-873. regulation of inducible nitric-oxide synthase in Kotera J, Fujishige K, and Omori K. 2000. macrophages by atrial natriuretic peptide. J Immunohistochemical localization of cGMP- Biol Chem 273:13444-13451. binding cGMP-specific phosphodiesterase Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, and (PDE5) in rat tissues. J Histochem Cytochem Shimizu T. 2005. Dual phase regulation of 48:685-693. experimental allergic encephalomyelitis by Kotera J, Fujishige K, Yuasa K, and Omori K. platelet-activating factor. Journal of 1999b. Characterization and phosphorylation Experimental Medicine 202:853-863. of PDE10A2, a novel alternative splice variant Kim NN, Huang YH, Goldstein I, Bischoff E, and of human phosphodiesterase that hydrolyzes Trais AM. 2001. Inhibition of cyclic GMP cAMP and cGMP. Biochem Biophys Res hydrolysis in human corpus cavernosum Commun 261:551-557. smooth muscle cells by , a novel, Kotera J, Grimes KA, Corbin JD, and Francis SH. selective phosphodiesterase type 5 inhibitor. 2003. CGMP-dependent protein kinase Life Sci 69:2249-2256. protects cGMP from hydrolysis by Kim YM, Chung HT, Kim SS, Han JA, Yoo YM, phosphodiesterase-5. Biochemical Journal Kim KM, Lee GH, Yun HY, Green A, Li J, 372:419-426. Simmons RL, and Billiar TR. 1999. Nitric oxide protects PC12 cells from serum deprivation- 186 Bibliografía Kotera J, Yanaka N, Fujishige K, Imai Y, Akatsuka Lassmann H, Bruck W, and Lucchinetti C. 2001. H, Ishizuka T, Kawashima K, and Omori K. Heterogeneity of multiple sclerosis 1997. Expression of rat cGMP-binding cGMP- pathogenesis: implications for diagnosis and specific phosphodiesterase mRNA in Purkinje therapy. Trends Mol Med 7:115-121. cell layers during postnatal neuronal Ledbetter JA, Parsons M, Martin PJ, Hansen JA, development. Eur J Biochem 249:434-442. Rabinovitch PS, and June CH. 1986. Antibody Kovala T, Sanwal BD, and Ball EH. 1997. binding to CD5 (Tp67) and Tp44 T cell surface Recombinant expression of a type IV, cAMP- molecules: effects on cyclic nucleotides, specific phosphodiesterase: characterization cytoplasmic free calcium, and cAMP-mediated and structure-function studies of deletion suppression. J Immunol 137:3299-3305. mutants. Biochemistry 36:2968-2976. Lee ME, Markowitz J, Lee JO, and Lee H. 2002. Kreutzberg GW. 1996. Microglia: a sensor for Crystal structure of phosphodiesterase 4D and pathological events in the CNS. Trends inhibitor complex(1). FEBS Lett 530:53. Neurosci 19:312-318. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Kuppenbender KD, Standaert DG, Feuerstein TJ, Belevych AE, Harvey RD, Richter W, Jin SL, Penney JB, Jr., Young AB, and Conti M, and Marks AR. 2005. Landwehrmeyer GB. 2000. Expression of Phosphodiesterase 4D deficiency in the NMDA receptor subunit mRNAs in ryanodine-receptor complex promotes heart neurochemically identified projection and failure and arrhythmias. Cell 123:25-35. interneurons in the human striatum. J Comp Lenzlinger PM, Morganti-Kossmann MC, Laurer Neurol 419:407-421. HL, and McIntosh TK. 2001. The duality of the Kuthe A, Magert H, Uckert S, Forssmann WG, inflammatory response to traumatic brain Stief CG, and Jonas U. 2000. Gene injury. Mol Neurobiol 24:169-181. expression of the phosphodiesterases 3A and Lewis GD and Semigran MJ. 2004. Type 5 5A in human corpus cavernosum penis. Eur phosphodiesterase inhibition in heart failure Urol 38:108-114. and pulmonary hypertension. Curr Heart Fail Lacroix S, Feinstein D, and Rivest S. 1998. The Rep 1:183-189. bacterial endotoxin lipopolysaccharide has the Lewis TS, Shapiro PS, and Ahn NG. 1998. Signal ability to target the brain in upregulating its transduction through MAP kinase cascades. membrane CD14 receptor within specific Adv Cancer Res 74:49-139. cellular populations. Brain Pathol 8:625-640. Li L, Yee C, and Beavo JA. 1999. CD3- and Lacroix S and Rivest S. 1998. Effect of acute CD28-dependent induction of PDE7 required systemic inflammatory response and cytokines for T cell activation. Science 283:848-851. on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) Liberto CM, Albrecht PJ, Herx LM, Yong VW, and in the rat brain. J Neurochem 70:452-466. Levison SW. 2004. Pro-regenerative properties of cytokine-activated astrocytes. J Lagente V, Martin-Chouly C, Boichot E, Martins Neurochem 89:1092-1100. MA, and Silva PM. 2005. Selective PDE4 inhibitors as potent anti-inflammatory drugs for Liliental J and Chang DD. 1998. Rack1, a receptor the treatment of airway diseases. Mem Inst for activated protein kinase C, interacts with Oswaldo Cruz 100 Suppl 1:131-136. integrin beta subunit. J Biol Chem 273:2379- 2383. Lal S, Sharma RK, McGregor C, and Macaulay RJ. 1999. Immunohistochemical localization of Lim J, Pahlke G, and Conti M. 1999. Activation of calmodulin-dependent cyclic the cAMP-specific phosphodiesterase phosphodiesterase in the human brain. PDE4D3 by phosphorylation. Identification and Neurochem Res 24:43-49. function of an inhibitory domain. J Biol Chem 274:19677-19685. Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Lin CS, Chow S, Lau A, Tu R, and Lue TF. 2001. Gresser M, and Huang Z. 2000. Regulation of human PDE5A2 intronic Conformational difference between PDE4 promoter by cAMP and cGMP: identification of apoenzyme and holoenzyme. Biochemistry a critical Sp1-. Biochem Biophys 39:6449-6458. Res Commun 280:693-699. Lalli E and Sassone-Corsi P. 1994. Signal Lin CS, Chow S, Lau A, Tu R, and Lue TF. 2002. transduction and gene regulation: the nuclear Human PDE5A gene encodes three PDE5 response to cAMP. J Biol Chem 269:17359- isoforms from two alternate promoters. Int J 17362. Impot Res 14:15-24. Lamontagne S, Meadows E, Luk P, Normandin D, Lin CS, Lau A, Tu R, and Lue TF. 2000. Muise E, Boulet L, Pon DJ, Robichaud A, Expression of three isoforms of cGMP-binding Robertson GS, Metters KM, and Nantel F. cGMP-specific phosphodiesterase (PDE5) in 2001. Localization of phosphodiesterase-4 human penile cavernosum. Biochem Biophys isoforms in the medulla and nodose ganglion Res Commun 268:628-635. of the squirrel monkey. Brain Res 920:84-96. Lincoln TM, Dey N, and Sellak H. 2001. Signal Lampson LA. 1987. Molecular-Bases of the transduction in smooth muscle - Invited review: Immune-Response to Neural Antigens. Trends cGMP-dependent protein kinase signaling in Neurosciences 10:211-216. mechanisms in smooth muscle: from the regulation of tone to gene expression. Journal of Applied Physiology 91:1421-1430.

187 Bibliografía Lindholm D, Heumann R, Meyer M, and Thoenen signaling by cyclic GMP. Pharmacological H. 1987. Interleukin-1 regulates synthesis of Reviews 52:375-413. nerve growth factor in non-neuronal cells of rat Lue LF, Brachova L, Civin WH, and Rogers J. sciatic nerve. Nature 330:658-659. 1996. Inflammation, A beta deposition, and Ling EA and Wong WC. 1993. The origin and neurofibrillary tangle formation as correlates of nature of ramified and amoeboid microglia: a Alzheimer's disease neurodegeneration. J historical review and current concepts. Glia Neuropathol Exp Neurol 55:1083-1088. 7:9-18. Lugnier C. 2006. Cyclic nucleotide Liu H and Maurice DH. 1998. Expression of cyclic phosphodiesterase (PDE) superfamily: a new GMP-inhibited phosphodiesterases 3A and 3B target for the development of specific (PDE3A and PDE3B) in rat tissues: differential therapeutic agents. Pharmacol Ther 109:366- subcellular localization and regulated 398. expression by cyclic AMP. Br J Pharmacol Luth HJ, Munch G, and Arendt T. 2002. Aberrant 125:1501-1510. expression of NOS isoforms in Alzheimer's Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, disease is structurally related to nitrotyrosine Gorseth E, Van Hamme J, Gresser MJ, and formation. Brain Research 953:135-143. Huang Z. 2001. Dissecting the - Lyman WD, Abrams GA, and Raine CS. 1989. dependent and independent bindings of pde4 Experimental autoimmune encephalomyelitis: inhibitors. Biochemistry 40:10179-10186. isolation and characterization of inflammatory Liu S, Veilleux A, Zhang L, Young A, Kwok E, cells from the central nervous system. J Laliberte F, Chung C, Tota MR, Dube D, Neuroimmunol 25:195-201. Friesen RW, and Huang Z. 2005. Dynamic Lynch MJ, Baillie GS, Mohamed A, Li X, activation of cystic fibrosis transmembrane Maisonneuve C, Klussmann E, Van Heeke G, conductance regulator by type 3 and type 4D and Houslay MD. 2005. RNA Silencing phosphodiesterase inhibitors. J Pharmacol Identifies PDE4D5 as the Functionally Exp Ther 314:846-854. Relevant cAMP Phosphodiesterase Interacting Livi GP, Kmetz P, McHale MM, Cieslinski LB, with {beta}Arrestin to Control the Protein Sathe GM, Taylor DP, Davis RL, Torphy TJ, Kinase A/AKAP79-mediated Switching of the and Balcarek JM. 1990. Cloning and {beta}2-Adrenergic Receptor to Activation of expression of cDNA for a human low-Km, ERK in HEK293B2 Cells. J Biol Chem rolipram-sensitive cyclic AMP 280:33178-33189. phosphodiesterase. Mol Cell Biol 10:2678- Lynch MJ, Hill EV, and Houslay MD. 2006. 2686. Intracellular targeting of phosphodiesterase-4 Lobban M, Shakur Y, Beattie J, and Houslay MD. underpins compartmentalized cAMP signaling. 1994. Identification of two splice variant forms Curr Top Dev Biol 75:225-259. of type-IVB cyclic AMP phosphodiesterase, Ma D, Wu P, Egan RW, Billah MM, and Wang P. DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in 1999. Phosphodiesterase 4B gene brain: selective localization in membrane and transcription is activated by lipopolysaccharide cytosolic compartments and differential and inhibited by interleukin-10 in human expression in various brain regions. Biochem J monocytes. Mol Pharmacol 55:50-57. 304 ( Pt 2):399-406. MacFarland RT, Zelus BD, and Beavo JA. 1991. Logothetis DE, Kurachi Y, Galper J, Neer EJ, and High concentrations of a cGMP-stimulated Clapham DE. 1987. The beta gamma subunits phosphodiesterase mediate ANP- induced of GTP-binding proteins activate the decreases in cAMP and steroidogenesis in muscarinic K+ channel in heart. Nature adrenal glomerulosa cells. J Biol Chem 325:321-326. 266:136-142. Loughney K, Hill TR, Florio VA, Uher L, Rosman MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, GJ, Wolda SL, Jones BA, Howard ML, and Houslay MD. 2000. ERK2 mitogen- McAllister-Lucas LM, Sonnenburg WK, Francis activated protein kinase binding, SH, Corbin JD, Beavo JA, and Ferguson K. phosphorylation, and regulation of the PDE4D 1998. Isolation and characterization of cDNAs cAMP-specific phosphodiesterases. THE encoding PDE5A, a human cGMP- binding, INVOLVEMENT OF COOH-TERMINAL cGMP-specific 3',5'-cyclic nucleotide DOCKING SITES AND NH2-TERMINAL UCR phosphodiesterase. Gene 216:139-147. REGIONS. J Biol Chem 275:16609-16617. Loughney K, Snyder PB, Uher L, Rosman GJ, MacKenzie SJ, Baillie GS, McPhee I, MacKenzie Ferguson K, and Florio VA. 1999. Isolation and C, Seamons R, McSorley T, Millen J, Beard characterization of PDE10A, a novel human 3', MB, Van Heeke G, and Houslay MD. 2002. 5'-cyclic nucleotide phosphodiesterase. Gene Long PDE4 cAMP specific 234:109-117. phosphodiesterases are activated by protein Loughney K, Taylor J, and Florio VA. 2005. 3',5'- kinase A-mediated phosphorylation of a single cyclic nucleotide phosphodiesterase 11A: serine residue in Upstream Conserved Region localization in human tissues. Int J Impot Res 1 (UCR1). Br J Pharmacol 136:421-433. 17:320-325. MacKenzie SJ, Yarwood SJ, Peden AH, Bolger Lucas KA, Pitari GM, Kazerounian S, Ruiz- GB, Vernon RG, and Houslay MD. 1998. Stewart I, Park J, Schulz S, Chepenik KP, and Stimulation of p70S6 kinase via a growth Waldman SA. 2000. Guanylyl cyclases and hormone-controlled phosphatidylinositol 3- kinase pathway leads to the activation of a 188 Bibliografía PDE4A cyclic AMP-specific plexus response to peripheral inflammatory phosphodiesterase in 3T3-F442A stimulus. Neuroscience 144:424-430. preadipocytes. Proc Natl Acad Sci U S A Martin-Padura I, Lostaglio S, Schneemann M, 95:3549-3554. Williams L, Romano M, Fruscella P, Panzeri C, Macphee CH, Harrison SA, and Beavo JA. 1986. Stoppacciaro A, Ruco L, Villa A, Simmons D, Immunological identification of the major and Dejana E. 1998. Junctional adhesion platelet low-Km cAMP phosphodiesterase: molecule, a novel member of the probable target for anti-thrombotic agents. immunoglobulin superfamily that distributes at Proc Natl Acad Sci U S A 83:6660-6663. intercellular junctions and modulates monocyte Male D, Rahman J, Pryce G, Tamatani T, and transmigration. J Cell Biol 142:117-127. Miyasaka M. 1994. Lymphocyte migration into Martínez A, Castro A, Gil C, Miralpeix M, Segarra the CNS modelled in vitro: roles of LFA-1, V, Domènech T, Beleta J, Palacios JM, Ryder ICAM-1 and VLA-4. Immunology 81:366-372. H, Miró X, Bonet C, Casacuberta JM, Azorin F, Manganiello VC, Murata T, Taira M, Belfrage P, Pina B, and Puigdomènech P. 2000. Benzyl and Degerman E. 1995a. Diversity in cyclic derivatives of 2,1,3-benzo- and nucleotide phosphodiesterase isoenzyme benzothieno[3,2-a]thiadiazine 2,2-dioxides: families. Arch Biochem Biophys 322:1-13. first phosphodiesterase 7 inhibitors. J Med Chem 43:683-689. Manganiello VC, Taira M, Degerman E, and Belfrage P. 1995b. Type III cGMP-inhibited Martinez I, Puerta C, Redondo C, and Garcia- cyclic nucleotide phosphodiesterases (PDE3 Merino A. 1999a. Type IV phosphodiesterase gene family). Cell Signal 7:445-455. inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential Manning CD, Burman M, Christensen SB, gene expression analysis of cytokines, Cieslinski LB, Essayan DM, Grous M, Torphy adhesion molecules and the inducible nitric TJ, and Barnette MS. 1999. Suppression of oxide synthase. J Neurol Sci 164:13-23. human inflammatory cell function by subtype- selective PDE4 inhibitors correlates with Martinez M, Fernandez E, Frank A, Guaza C, de inhibition of PDE4A and PDE4B. Br J la Fuente M, and Hernanz A. 1999b. Increased Pharmacol 128:1393-1398. cerebrospinal fluid cAMP levels in Alzheimer's disease. Brain Res 846:265-267. Marchmont RJ, Ayad SR, and Houslay MD. 1981. Purification and properties of the insulin- Martinez SE, Wu AY, Glavas NA, Tang XB, Turley stimulated cyclic AMP phosphodiesterase from S, Hol WGJ, and Beavo JA. 2002. The two rat liver plasma membranes. Biochem J GAF domains in phosphodiesterase 2A have 195:645-652. distinct roles in dimerization and in cGMP binding. Proceedings of the National Academy Marchmont RJ and Houslay MD. 1980. A of Sciences of the United States of America peripheral and an intrinsic enzyme constitute 99:13260-13265. the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem J Mata M, Sarria B, Buenestado A, Cortijo J, Cerda 187:381-392. M, and Morcillo EJ. 2005. Phosphodiesterase 4 inhibition decreases MUC5AC expression Marcoz P, Nemoz G, Prigent AF, and Lagarde M. induced by epidermal growth factor in human 1993. Phosphatidic acid stimulates the airway epithelial cells. Thorax 60:144-152. rolipram-sensitive cyclic nucleotide phosphodiesterase from rat thymocytes. Mato M, Ookawara S, Sakamoto A, Aikawa E, Biochim Biophys Acta 1176:129-136. Ogawa T, Mitsuhashi U, Masuzawa T, Suzuki H, Honda M, Yazaki Y, Watanabe E, Luoma J, Marinissen MJ and Gutkind JS. 2001. G-protein- Yla-Herttuala S, Fraser I, Gordon S, and coupled receptors and signaling networks: Kodama T. 1996. Involvement of specific emerging paradigms. Trends Pharmacol Sci macrophage-lineage cells surrounding 22:368-376. arterioles in barrier and scavenger function in Marjamaki A, Sato M, BouetAlard R, Yang Q, brain cortex. Proc Natl Acad Sci U S A LimonBoulez I, Legrand C, and Lanier SM. 93:3269-3274. 1997. Factors determining the specificity of Matsuda M, Tsukada N, Miyagi K, and signal transduction by guanine nucleotide- Yanagisawa N. 1995. Adhesion of binding protein-coupled receptors - Integration Lymphocytes to Endothelial-Cells in of stimulatory and inhibitory input to the Experimental Allergic Encephalomyelitis effector adenylyl cyclase. Journal of Biological Before and After Treatment with Endotoxin Chemistry 272:16466-16473. Lipopolysaccharide. International Archives of Marko D, Romanakis K, Zankl H, Furstenberger Allergy and Immunology 106:335-344. G, Steinbauer B, and Eisenbrand G. 1998. Maurice DH. 2005. Cyclic nucleotide Induction of apoptosis by an inhibitor of cAMP- phosphodiesterase-mediated integration of specific PDE in malignant murine carcinoma cGMP and cAMP signaling in cells of the cells overexpressing PDE activity in cardiovascular system. Front Biosci 10:1221- comparison to their nonmalignant 1228. counterparts. Cell Biochem Biophys 28:75- 101. Mayr B and Montminy M. 2001. Transcriptional regulation by the phosphorylation-dependent Marques F, Sousa JC, Correia-Neves M, Oliveira factor CREB. Nat Rev Mol Cell Biol 2:599-609. P, Sousa N, and Palha JA. 2007. The choroid McAleer MA, Breen MA, White NL, and Matthews N. 1999. PABC11 (also known as MOAT-C 189 Bibliografía and MRP5), a member of the ABC family of neuroinflammation and patterning. Trends proteins, has anion transporter activity but Pharmacol Sci 20:73-78. does not confer multidrug resistance when Mergia E, Russwurm M, Zoidl G, and Koesling D. overexpressed in human embryonic kidney 2003. Major occurrence of the new 293 cells. Journal of Biological Chemistry alpha2beta1 isoform of NO-sensitive guanylyl 274:23541-23548. cyclase in brain. Cell Signal 15:189-195. McAllister-Lucas LM, Sonnenburg WK, Kadlecek Mery PF, Pavoine C, Pecker F, and Fischmeister A, Seger D, Trong HL, Colbran JL, Thomas R. 1995. Erythro-9-(2-hydroxy-3-nonyl)adenine MK, Walsh KA, Francis SH, Corbin JD, and . inhibits cyclic GMP-stimulated 1993. The structure of a bovine lung cGMP- phosphodiesterase in isolated cardiac binding, cGMP-specific phosphodiesterase myocytes. Mol Pharmacol 48:121-130. deduced from a cDNA clone. J Biol Chem 268:22863-22873. Mhaouty S, Cohentannoudji J, BouetAlard R, LimonBoulez I, Maltier JP, and Legrand C. McCahill A, McSorley T, Huston E, Hill EV, Lynch 1995. Characteristics of the Alpha(2)/Beta(2)- MJ, Gall I, Keryer G, Lygren B, Tasken K, Van Adrenergic Receptor-Coupled Adenylyl- Heeke G, and Houslay MD. 2005. In resting Cyclase System in Rat Myometrium During COS1 cells a dominant negative approach Pregnancy. Journal of Biological Chemistry shows that specific, anchored PDE4 cAMP 270:11012-11016. phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of Michaeli T, Bloom TJ, Martins T, Loughney K, AKAP-tethered protein kinase A type II located Ferguson K, Riggs M, Rodgers L, Beavo JA, in the centrosomal region. Cell Signal 17:1158- and Wigler M. 1993. Isolation and 1173. characterization of a previously undetected human cAMP phosphodiesterase by McCahill A, Warwicker J, Bolger GB, Houslay MD, complementation of cAMP phosphodiesterase- and Yarwood SJ. 2002. The RACK1 scaffold deficient Saccharomyces cerevisiae. J Biol protein: a dynamic cog in cell response Chem 268:12925-12932. mechanisms. Mol Pharmacol 62:1261-1273. Michel JJ and Scott JD. 2002. AKAP mediated McGeer PL, McGeer E, Rogers J, and Sibley J. signal transduction. Annu Rev Pharmacol 1990. Anti-inflammatory drugs and Alzheimer Toxicol 42:235-257. disease [letter] [see comments]. Lancet 335:1037. Michie AM, Lobban M, Muller T, Harnett MM, and Houslay MD. 1996. Rapid regulation of PDE-2 McGeer PL and McGeer EG. 1995. The and PDE-4 cyclic AMP phosphodiesterase inflammatory response system of brain: activity following ligation of the T cell antigen implications for therapy of Alzheimer and other receptor on thymocytes: analysis using the neurodegenerative diseases. Brain Res Rev selective inhibitors erythro-9-(2- hydroxy-3- 21:195-218. nonyl)-adenine (EHNA) and rolipram. Cell McGeer PL and McGeer EG. 2001. Inflammation, Signal 8:97-110. autotoxicity and Alzheimer disease. Neurobiol Middendorff R, Davidoff MS, Behrends S, Mewe Aging 22:799-809. M, Miethens A, and Muller D. 2000. Multiple McLaughlin ME, Sandberg MA, Berson EL, and roles of the messenger molecule cGMP in Dryja TP. 1993a. Recessive mutations in the testicular function. Andrologia 32:55-59. gene encoding the beta-subunit of rod Milatovich A, Bolger G, Michaeli T, and Francke phosphodiesterase in patients with retinitis U. 1994. Chromosome localizations of genes pigmentosa. Nat Genet 4:130-134. for five cAMP-specific phosphodiesterases in McLaughlin MM, Cieslinski LB, Burman M, Torphy man and mouse. Somat Cell Mol Genet 20:75- TJ, and Livi GP. 1993b. A low-Km, rolipram- 86. sensitive, cAMP-specific phosphodiesterase Millar JK, James R, Brandon NJ, and Thomson from human brain. Cloning and expression of PA. 2004. DISC1 and DISC2: discovering and cDNA, biochemical characterization of dissecting molecular mechanisms underlying recombinant protein, and tissue distribution of psychiatric illness. Ann Med 36:367-378. mRNA. J Biol Chem 268:6470-6476. Millar JK, Pickard BS, Mackie S, James R, McPhee I, Yarwood SJ, Scotland G, Huston E, Christie S, Buchanan SR, Malloy MP, Chubb Beard MB, Ross AH, Houslay ES, and JE, Huston E, Baillie GS, Thomson PA, Hill Houslay MD. 1999. Association with the SRC EV, Brandon NJ, Rain JC, Camargo LM, family tyrosyl kinase LYN triggers a Whiting PJ, Houslay MD, Blackwood DH, Muir conformational change in the catalytic region WJ, and Porteous DJ. 2005. DISC1 and of human cAMP-specific phosphodiesterase PDE4B are interacting genetic factors in HSPDE4A4B. Consequences for rolipram schizophrenia that regulate cAMP signaling. inhibition. J Biol Chem 274:11796-11810. Science 310:1187-1191. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu Millhouse OE. 1987. Granule cells of the olfactory DT, and Conti M. 2003. PDE4D plays a critical tubercle and the question of the islands of role in the control of airway smooth muscle Calleja. J Comp Neurol 265:1-24. contraction. FASEB J 17:1831-1841. Miró X, Pérez-Torres S, Artigas F, Puigdomènech Mennicken F, Maki R, De Souza EB, and Quirion P, Palacios JM, and Mengod G. 2002a. R. 1999. Chemokines and chemokine Regulation of cAMP phosphodiesterase receptors in the CNS: a possible role in mRNAs expression in rat brain by acute and

190 Bibliografía chronic fluoxetine treatment. An in situ release of adhesion molecules in human hybridization study. Neuropharmacology endothelial cells. Am J Physiol 270:H807- 43:1148-1157. H816. Miró X, Pérez-Torres S, Palacios JM, Morimoto BH and Koshland DEJ. 1991. Puigdomènech P, and Mengod G. 2001. Identification of cyclic AMP as the response Differential distribution of cAMP-specific regulator for neurosecretory potentiation: a phosphodiesterase 7A mRNA in rat brain and memory model system. Proc Natl Acad Sci U peripheral organs. Synapse 40:201-214. S A 88:10835-10839. Miró X, Pérez-Torres S, Puigdomènech P, Morini M, Roccatagliata L, Dell'Eva R, Pedemonte Palacios JM, and Mengod G. 2002b. E, Furlan R, Minghelli S, Giunti D, Pfeffer U, Differential distribution of PDE4D splice variant Marchese M, Noonan D, Mancardi G, Albini A, mRNAs in rat brain suggests association with and Uccelli A. 2004. alpha-Lipoic acid is specific pathways and presynaptical effective in prevention and treatment of localization. Synapse 45:259-269. experimental autoimmune encephalomyelitis. Mo E, Amin H, Bianco IH, and Garthwaite J. 2004. Journal of Neuroimmunology 148:146-153. Kinetics of a cellular nitric Morrissey SP, Deichmann R, Syha J, Simonis C, oxide/cGMP/phosphodiesterase-5 pathway. J Zettl U, Archelos JJ, Jung S, Stodal H, Biol Chem 279:26149-26158. Lassmann H, Toyka KV, Haase A, and Mochly-Rosen D, Smith BL, Chen CH, Disatnik Hartung HP. 1996. Partial inhibition of AT-EAE MH, and Ron D. 1995. Interaction of protein by an antibody to ICAM-1: clinico-histological kinase C with RACK1, a receptor for activated and MRI studies. J Neuroimmunol 69:85-93. C-kinase: a role in beta protein kinase C Mseeh F, Colman RF, and Colman RW. 2000. mediated signal transduction. Biochem Soc Inactivation of platelet PDE2 by an affinity Trans 23:596-600. label: 8-[(4-bromo-2, 3-dioxobutyl)thio]cAMP. Moncada S, Palmer RM, and Higgs EA. 1991. Thromb Res 98:395-401. Nitric oxide: physiology, pathophysiology, and Muller DM, Pender MP, and Greer JM. 2004. pharmacology. Pharmacol Rev 43:109-142. Chemokines and chemokine receptors: Montero-Menei CN, Sindji L, Garcion E, Mege M, potential therapeutic targets in multiple Couez D, Gamelin E, and Darcy F. 1996. Early sclerosis. Curr Drug Targets Inflamm Allergy events of the inflammatory reaction induced in 3:279-290. rat brain by lipopolysaccharide intracerebral Muller T, Engels P, and Fozard JR. 1996. injection: relative contribution of peripheral Subtypes of the type 4 cAMP monocytes and activated microglia. Brain Res phosphodiesterases: structure, regulation and 724:55-66. selective inhibition. Trends Pharmacol Sci Montero-Menei CN, Sindji L, Pouplard-Barthelaix 17:294-298. A, Jehan F, Denechaud L, and Darcy F. 1994. Murad F. 1998. Nitric oxide signaling: would you Lipopolysaccharide intracerebral believe that a simple free radical could be a administration induces minimal inflammatory second messenger, autacoid, paracrine reaction in rat brain. Brain Res 653:101-111. substance, neurotransmitter, and hormone? Montixi C, Langlet C, Bernard AM, Thimonier J, Recent Prog Horm Res 53:43-59. Dubois C, Wurbel MA, Chauvin JP, Pierres M, Muradov KG, Granovsky AE, and Artemyev NO. and He HT. 1998. Engagement of T cell 2003. Mutation in rod PDE6 linked to receptor triggers its recruitment to low-density congenital stationary night blindness impairs detergent-insoluble membrane domains. the enzyme inhibition by its gamma-subunit. EMBO J 17:5334-5348. Biochemistry 42:3305-3310. Montorsi F, Corbin J, and Phillips S. 2004. Review Murakami M and Kudo I. 2004. Recent advances of phosphodiesterases in the urogenital in molecular biology and physiology of the system: new directions for therapeutic prostaglandin E2-biosynthetic pathway. Prog intervention. J Sex Med 1:322-336. Lipid Res 43:3-35. Moore AR and Willoughby DA. 1995. The Role of Murata T, Sugatani T, Shimizu K, Manganiello VC, Camp Regulation in Controlling Inflammation. and Tagawa T. 2001. Phosphodiesterase 3 as Clinical and Experimental Immunology a potential target for therapy of malignant 101:387-389. tumors in the submandibular gland. Anticancer Moore CS, Earl N, Frenette R, Styhler A, Mancini Drugs 12:79-83. JA, Nicholson DW, Hebb AL, Owens T, and Murata T, Sugatani T, and Tagawa T. 2000. Robertson GS. 2006. Peripheral Expression of phosphodiesterase 3 in rat phosphodiesterase 4 inhibition produced by 4- submandibular gland. Arch Oral Biol 45:1043- [2-(3,4-Bis-difluoromethoxyphenyl)-2-[4- 1047. (1,1,1,3,3,3-hexafluoro-2-hydrox ypropan-2-yl)- Murthy KS, Zhou HP, and Makhlouf GM. 2002. phenyl]-ethyl]-3-methylpyridine-1-oxide (L- PKA-dependent activation of PDE3A and 826,141) prevents experimental autoimmune PDE4 and inhibition of adenylyl cyclase V/VI in encephalomyelitis. J Pharmacol Exp Ther smooth muscle. American Journal of 319:63-72. Physiology-Cell Physiology 282:C508-C517. Morandini R, Ghanem G, Portier-Lemarie A, Nadeau S and Rivest S. 1999. Regulation of the Robaye B, Renaud A, and Boeynaems JM. gene encoding tumor necrosis factor alpha 1996. Action of cAMP on expression and (TNF-alpha) in the rat brain and pituitary in

191 Bibliografía response in different models of systemic Norton AW, Hosier S, Terew JM, Li N, Dhingra A, immune challenge. J Neuropathol Exp Neurol Vardi N, Baehr W, and Cote RH. 2005. 58:61-77. Evaluation of the 17-kDa prenyl-binding Nagakura A, Niimura M, and Takeo S. 2002. protein as a regulatory protein for Effects of a phosphodiesterase IV inhibitor phototransduction in retinal photoreceptors. J rolipram on microsphere embolism-induced Biol Chem 280:1248-1256. defects in memory function and cerebral cyclic Norton WT, Aquino DA, Hozumi I, Chiu FC, and AMP signal transduction system in rats. Br J Brosnan CF. 1992. Quantitative aspects of Pharmacol 135:1783-1793. reactive gliosis: a review. Neurochem Res Nakajima K and Kohsaka S. 1993. Functional 17:877-885. roles of microglia in the brain. Neurosci Res O'Brien J. 2003. Behavioral symptoms in vascular 17:187-203. cognitive impairment and vascular dementia. Nakata A, Ogawa K, Sasaki T, Koyama N, Wada Int Psychogeriatr 15 Suppl 1:133-138. K, Kotera J, Kikkawa H, Omori K, and O'Connell JC, McCallum JF, McPhee I, Wakefield Kaminuma O. 2002. Potential role of J, Houslay ES, Wishart W, Bolger G, Frame M, phosphodiesterase 7 in human T cell function: and Houslay MD. 1996. The SH3 domain of comparative effects of two phosphodiesterase Src tyrosyl protein kinase interacts with the N- inhibitors. Clin Exp Immunol 128:460-466. terminal splice region of the PDE4A cAMP- Naro F, Sette C, Vicini E, De A, V, Grange M, specific phosphodiesterase RPDE-6 Conti M, Lagarde M, Molinaro M, Adamo S, (RNPDE4A5). Biochem J 318 ( Pt 1):255-261. and Nemoz G. 1999. Involvement of type 4 O'Connor V, Genin A, Davis S, Karishma KK, cAMP-phosphodiesterase in the myogenic Doyere V, De Zeeuw CI, Sanger G, Hunt SP, differentiation of L6 cells. Mol Biol Cell Richter-Levin G, Mallet J, Laroche S, Bliss TV, 10:4355-4367. and French PJ. 2004. Differential amplification Nemoz G, Sette C, and Conti M. 1997. Selective of intron-containing transcripts reveals long activation of rolipram-sensitive, cAMP-specific term potentiation-associated up-regulation of phosphodiesterase isoforms by phosphatidic specific Pde10A phosphodiesterase splice acid. Mol Pharmacol 51:242-249. variants. J Biol Chem 279:15841-15849. Netherton SJ and Maurice DH. 2005. Vascular O'Donnell JM and Zhang HT. 2004a. endothelial cell cyclic nucleotide Antidepressant effects of inhibitors of cAMP phosphodiesterases and regulated cell phosphodiesterase (PDE4). Trends Pharmacol migration: implications in angiogenesis. Mol Sci 25:158-163. Pharmacol 67:263-272. O'Donnell JM and Zhang HT. 2004b. Neumann H. 2000. The immunological Antidepressant effects of inhibitors of cAMP microenvironment in the CNS: implications on phosphodiesterase (PDE4). Trends Pharmacol neuronal cell death and survival. J Neural Sci 25:158-163. Transm Suppl 59:59-68. Obernolte R, Ratzliff J, Baecker PA, Daniels DV, Neumann H, Cavalie A, Jenne DE, and Wekerle Zuppan P, Jarnagin K, and Shelton ER. 1997. H. 1995. Induction of MHC class I genes in Multiple splice variants of phosphodiesterase neurons. Science 269:549-552. PDE4C cloned from human lung and testis. Biochim Biophys Acta 1353:287-297. Neumann H, Schmidt H, Cavalie A, Jenne D, and Wekerle H. 1997. Major histocompatibility Ogawa R, Streiff MB, Bugayenko A, and Kato GJ. complex (MHC) class I gene expression in 2002. Inhibition of PDE4 phosphodiesterase single neurons of the central nervous system: activity induces growth suppression, differential regulation by interferon (IFN)- apoptosis, glucocorticoid sensitivity, p53, and gamma and tumor necrosis factor (TNF)- p21(WAF1/CIP1) proteins in human acute alpha. J Exp Med 185:305-316. lymphoblastic leukemia cells. Blood 99:3390- 3397. Neumann H, Schweigreiter R, Yamashita T, Rosenkranz K, Wekerle H, and Barde YA. Ohm TG, Schmitt M, Bohl J, and Lemmer B. 1997. 2002. Tumor necrosis factor inhibits neurite Decrease in adenylate cyclase activity outgrowth and branching of hippocampal antecedes neurofibrillary tangle formation. neurons by a rho-dependent mechanism. J Neurobiol Aging 18:275-279. Neurosci 22:854-862. Oki N, Takahashi SI, Hidaka H, and Conti M. Nikulina E, Tidwell JL, Dai HN, Bregman BS, and 2000. Short term feedback regulation of cAMP Filbin MT. 2004. The phosphodiesterase in FRTL-5 thyroid cells. Role of PDE4D3 inhibitor rolipram delivered after a spinal cord phosphodiesterase activation. J Biol Chem lesion promotes axonal regeneration and 275:10831-10837. functional recovery. Proc Natl Acad Sci U S A Ollivier V, Parry GCN, Cobb RR, de Prost D, and 101:8786-8790. Mackman N. 1996. Elevated cyclic AMP Nishi T, Kimura Y, and Nakagawa K. 2000. inhibits NF-kappaB-mediated transcription in [Research and development of cilostazol: an human monocytic cells and endothelial cells. J antiplatelet agent]. Yakugaku Zasshi Biol Chem 271:20828-20835. 120:1247-1260. Omburo GA, Jacobitz S, Torphy TJ, and Colman Norenberg MD. 1994. Astrocyte responses to RW. 1998. Critical role of conserved histidine CNS injury. J Neuropathol Exp Neurol 53:213- pairs HNXXH and HDXXH in recombinant 220.

192 Bibliografía human phosphodiesterase 4A. Cell Signal Pérez-Torres S, Miró X, Palacios JM, Cortés R, 10:491-497. Puigdomènech P, and Mengod G. 2000. Osborn L. 1990. Leukocyte adhesion to Phosphodiesterase type 4 isozymes endothelium in inflammation. Cell 62:3-6. expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram Otmakhov N, Khibnik L, Otmakhova N, Carpenter binding autoradiography. Comparison with S, Riahi S, Asrican B, and Lisman J. 2004. monkey and rat brain. J Chem Neuroanat Forskolin-induced LTP in the CA1 20:349-374. hippocampal region is NMDA receptor dependent. J Neurophysiol 91:1955-1962. Perry VH, Anthony DC, Bolton SJ, and Brown HC. 1997. The blood-brain barrier and the Owens RJ, Catterall C, Batty D, Jappy J, Russell inflammatory response. Mol Med Today 3:335- A, Smith B, O'Connell J, and Perry MJ. 1997. 341. Human phosphodiesterase 4A: characterization of full-length and truncated Perry VH, Bell MD, Brown HC, and Matyszak MK. enzymes expressed in COS cells. Biochem J 1995. Inflammation in the Nervous-System. 326 ( Pt 1):53-60. Current Opinion in Neurobiology 5:636-641. Palm D, Wiemer G, and Dietz J. 1981. Efflux of Perry VH and Gordon S. 1991. Macrophages and 3',5'-Camp from Immature Rat Erythrocytes - the nervous system. Int Rev Cytol 125:203- Dependence on Intracellular Concentrations of 244. Camp and Atp. Naunyn-Schmiedebergs Pian MS and Dobbs LG. 1995. Evidence for G- Archives of Pharmacology 317:372. Beta-Gamma-Mediated Cross-Talk in Primary Palmer AM. 2002. Pharmacotherapy for Cultures of Lung Alveolar Cells. Journal of Alzheimer's disease: progress and prospects. Biological Chemistry 270:7427-7430. Trends Pharmacol Sci 23:426-433. Pierce KL, Premont RT, and Lefkowitz RJ. 2002. Paris D, Town T, Parker TA, Tan J, Humphrey J, Seven-transmembrane receptors. Nat Rev Mol Crawford F, and Mullan M. 1999. Inhibition of Cell Biol 3:639-650. Alzheimer's beta-amyloid induced vasoactivity Pifarre P, Garcia A, and Mengod G. 2007. and proinflammatory response in microglia by Species differences in the localization of a cGMP-dependent mechanism. Exp Neurol soluble guanylyl cyclase subunits in monkey 157:211-221. and rat brain. J Comp Neurol 500:942-957. Parkes JD, Thompson C, Brennan L, Gajraj N, Pilewski JM and Frizzell RA. 1999. Role of CFTR Howcroft B, and Ruiz J. 1984. Rolipram in in airway disease. Physiol Rev 79:S215-S255. Parkinson's disease. Adv Neurol 40:563-565. Platzer C, Fritsch E, Elsner T, Lehmann MH, Volk Parma J, Duprez L, Vansande J, Cochaux P, HD, and Prosch S. 1999. Cyclic adenosine Gervy C, Mockel J, Dumont J, and Vassart G. monophosphate-responsive elements are 1993. Somatic Mutations in the Thyrotropin involved in the transcriptional activation of the Receptor Gene Cause Hyperfunctioning human IL-10 gene in monocytic cells. Eur J Thyroid Adenomas. Nature 365:649-651. Immunol 29:3098-3104. Parsian A, Todd RD, Cloninger CR, Hoffman PL, Pober JS, Slowik MR, De Luca LG, and Ritchie Ovchinnikova L, Ikeda H, Tabakoff B, Schuckit AJ. 1993. Elevated cyclic AMP inhibits MA, Rappaport M, Tsuang J, Salaspuro M, endothelial cell synthesis and expression of Monteiro MG, Balant LP, Davidson C, Ogata TNF-induced endothelial leukocyte adhesion M, Yamashita I, and Grant BF. 1996. Platelet molecule-1, and vascular cell adhesion adenylyl cyclase activity in alcoholics and molecule-1, but not intercellular adhesion subtypes of alcoholics. Alcoholism-Clinical and molecule-1. J Immunol 150:5114-5123. Experimental Research 20:745-751. Polfliet MM, van d, V, Dopp EA, Kesteren- Pashenkov M, Teleshova N, Kouwenhoven M, Hendrikx EM, Van Rooijen N, Dijkstra CD, and Smirnova T, Jin YP, Kostulas V, Huang YM, van den Berg TK. 2002. The role of Pinegin B, Boiko A, and Link H. 2002. perivascular and meningeal macrophages in Recruitment of dendritic cells to the experimental allergic encephalomyelitis. J cerebrospinal fluid in bacterial neuroinfections. Neuroimmunol 122:1-8. J Neuroimmunol 122:106-116. Polli JW and Kincaid RL. 1994. Expression of a Paxinos G and Watson C. 1998. The Rat Brain in calmodulin-dependent phosphodiesterase stereotaxic coordinates. San Diego: Academic isoform (PDE1B1) correlates with brain Press. regions having extensive dopaminergic Pérez-Torres S, Cortés R, Tolnay M, Probst A, innervation. J Neurosci 14:1251-1261. Palacios JM, and Mengod G. 2003. Alterations Polman CH, Dijkstra CD, Sminia T, and Koetsier on phosphodiesterase type 7 and 8 isozyme JC. 1986. Immunohistological analysis of mRNA expression in Alzheimer's disease macrophages in the central nervous system of brains examined by in situ hybridization. Exp Lewis rats with acute experimental allergic Neurol 182:322-334. encephalomyelitis. J Neuroimmunol 11:215- Pérez-Torres S and Mengod G. 2002. cAMP- 222. specific phosphodiesterases expression in Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Alzheimer's disease brains. In Satoh K, Suzuki and Esiri MM. 2005. Demyelinated neocortical S, and Matsunaga M, editors. Advances in lesions in marmoset autoimmune Brain Research. Amsterdam: Elsevier Science encephalomyelitis mimic those in multiple B.V. p 127-138. sclerosis. Brain 128:2713-2721.

193 Bibliografía Porter AG and Janicke RU. 1999. Emerging roles Reinhardt RR and Bondy CA. 1996. Differential of caspase-3 in apoptosis. Cell Death and cellular pattern of gene expression for two Differentiation 6:99-104. distinct cGMP-inhibited cyclic nucleotide Pouyssegur J and Lenormand P. 2003. Fidelity phosphodiesterases in developing and mature and spatio-temporal control in MAP kinase rat brain. Neuroscience 72:567-578. (ERKs) signalling. Eur J Biochem 270:3291- Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, 3299. Manganiello VC, and Bondy CA. 1995. Prickaerts J, Koopmans G, Blokland A, and Distinctive anatomical patterns of gene Scheepens A. 2004a. Learning and adult expression for cGMP-inhibited cyclic neurogenesis: survival with or without nucleotide phosphodiesterases. J Clin Invest proliferation? Neurobiol Learn Mem 81:1-11. 95:1528-1538. Prickaerts J, Sik A, van Staveren WC, Koopmans Rentero C, Monfort A, and Puigdomènech P. G, Steinbusch HW, van der Staay FJ, de 2003. Identification and distribution of different Vente J, and Blokland A. 2004b. mRNA variants produced by differential Phosphodiesterase type 5 inhibition improves splicing in the human phosphodiesterase 9A early memory consolidation of object gene. Biochem Biophys Res Commun information. Neurochem Int 45:915-928. 301:686-692. Pryce G, Male D, Campbell I, and Greenwood J. Repaske DR, Corbin JG, Conti M, and Goy MF. 1997. Factors controlling T-cell migration 1993. A cyclic GMP-stimulated cyclic across rat cerebral endothelium in vitro. J nucleotide phosphodiesterase gene is highly Neuroimmunol 75:84-94. expressed in the limbic system of the rat brain. Neuroscience 56:673-686. Pyne NJ and Furman BL. 2003. Cyclic nucleotide phosphodiesterases in pancreatic islets. Rich TC, Fagan KA, Tse TE, Schaack J, Cooper Diabetologia 46:1179-1189. DM, and Karpen JW. 2001. A uniform extracellular stimulus triggers distinct cAMP Quan N, Stern EL, Whiteside MB, and Herkenham signals in different compartments of a simple M. 1999. Induction of pro-inflammatory cell. Proc Natl Acad Sci U S A 98:13049- cytokine mRNAs in the brain after peripheral 13054. injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol Richard FJ, Tsafriri A, and Conti M. 2001. Role of 93:72-80. phosphodiesterase type 3A in rat oocyte maturation. Biol Reprod 65:1444-1451. Quan N, Whiteside M, and Herkenham M. 1998. Cyclooxygenase 2 mRNA expression in rat Richter W. 2002. 3 ',5 '-cyclic nucleotide brain after peripheral injection of phosphodiesterases class III: Members, lipopolysaccharide. Brain Res 802:189-197. structure, and catalytic mechanism. Proteins- Structure Function and Genetics 46:278-286. Quan N, Whiteside M, Kim L, and Herkenham M. 1997. Induction of inhibitory factor Richter W and Conti M. 2002. Dimerization of the kappaBalpha mRNA in the central nervous type 4 cAMP-specific phosphodiesterases is system after peripheral lipopolysaccharide mediated by the upstream conserved regions administration: an in situ hybridization (UCRs). Journal of Biological Chemistry histochemistry study in the rat. Proc Natl Acad 277:40212-40221. Sci U S A 94:10985-10990. Richter W and Conti M. 2004. The oligomerization RALL TW, Sutherland EW, and WOSILAIT WD. state determines regulatory properties and 1956. The relationship of epinephrine and inhibitor sensitivity of type 4 cAMP-specific glucagon to liver phosphorylase. III. phosphodiesterases. J Biol Chem 279:30338- Reactivation of liver phosphorylase in slices 30348. and in extracts. J Biol Chem 218:483-495. Risau W, Engelhardt B, and Wekerle H. 1990. Ramos BP, Birnbaum SG, Lindenmayer I, Newton Immune function of the blood-brain barrier: SS, Duman RS, and Arnsten AF. 2003. incomplete presentation of protein (auto- Dysregulation of protein kinase a signaling in )antigens by rat brain microvascular the aged prefrontal cortex: new strategy for endothelium in vitro. J Cell Biol 110:1757- treating age-related cognitive decline. Neuron 1766. 40:835-845. Robichaud A, Stamatiou PB, Jin SL, Lachance N, Ransohoff RM. 2002. Chemokines in neurological Macdonald D, Laliberte F, Liu S, Huang Z, trauma models. Ann N Y Acad Sci 961:346- Conti M, and Chan CC. 2002. Deletion of 349. phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a Ransohoff RM, Kivisakk P, and Kidd G. 2003. behavioral correlate of emesis. J Clin Invest Three or more routes for leukocyte migration 110:1045-1052. into the central nervous system. Nat Rev Immunol 3:569-581. Rocque WJ, Holmes WD, Patel IR, Dougherty RW, Ittoop O, Overton L, Hoffman CR, Wisely Reeves ML, Leigh BK, and England PJ. 1987. The GB, Willard DH, and Luther MA. 1997. identification of a new cyclic nucleotide Detailed characterization of a purified type 4 phosphodiesterase activity in human and phosphodiesterase, HSPDE4B2B: guinea-pig cardiac ventricle. Implications for differentiation of high- and low-affinity (R)- the mechanism of action of selective rolipram binding. Protein Expr Purif 9:191-202. phosphodiesterase inhibitors. Biochem J 241:535-541.

194 Bibliografía Rodefer JS, Murphy ER, and Baxter MG. 2005. Sakaguchi T, Nakamura S, Suzuki S, Oda T, PDE10A inhibition reverses subchronic PCP- Ichiyama A, Baba S, and Okamoto T. 1999. induced deficits in attentional set-shifting in Participation of platelet-activating factor in the rats. Eur J Neurosci 21:1070-1076. lipopolysaccharide-induced liver injury in Rogers J, Webster S, Lue LF, Brachova L, Civin partially hepatectomized rats. Hepatology WH, Emmerling M, Shivers B, Walker D, and 30:959-967. McGeer P. 1996. Inflammation and Salanova M, Chun SY, Iona S, Puri C, Stefanini Alzheimer's disease pathogenesis. Neurobiol M, and Conti M. 1999. Type 4 cyclic adenosine Aging 17:681-686. monophosphate-specific phosphodiesterases Rohl C, Lucius R, and Sievers J. 2007. The effect are expressed in discrete subcellular of activated microglia on astrogliosis compartments during rat spermiogenesis. parameters in astrocyte cultures. Brain Res Endocrinology 140:2297-2306. 1129:43-52. Sanchez AJ, Puerta C, Ballester S, Gonzalez P, Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, Arriaga A, and Garcia-Merino A. 2005. and Mochly-Rosen D. 1994. Cloning of an Rolipram impairs NF-kappaB activity and intracellular receptor for protein kinase C: a MMP-9 expression in experimental homolog of the beta subunit of G proteins. autoimmune encephalomyelitis. J Proc Natl Acad Sci U S A 91:839-843. Neuroimmunol 168:13-20. Rondinone CM, Carvalho E, Rahn T, Manganiello Sandberg M, Natarajan V, Ronander I, Kalderon VC, Degerman E, and Smith UP. 2000. D, Walter U, Lohmann SM, and Jahnsen T. Phosphorylation of PDE3B by 1989. Molecular-Cloning and Predicted Full- phosphatidylinositol 3-kinase associated with Length Amino-Acid Sequence of the Type I- the insulin receptor. J Biol Chem 275:10093- Beta-Isozyme of Cgmp-Dependent Protein- 10098. Kinase from Human-Placenta - Tissue Distribution and Developmental-Changes in Rose GM, Hopper A, De Vivo M, and Tehim A. Rat. Febs Letters 255:321-329. 2005. Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des Sano R, Miki T, Suzuki Y, Shimada F, Taira M, 11:3329-3334. Kanatsuka A, Makino H, Hashimoto N, and Saito Y. 2001. Analysis of the insulin-sensitive Rosen RC and Kostis JB. 2003. Overview of phosphodiesterase 3B gene in type 2 phosphodiesterase 5 inhibition in erectile diabetes. Diabetes Res Clin Pract 54:79-88. dysfunction. Am J Cardiol 92:9M-18M. Santambrogio L, Belyanskaya SL, Fischer FR, Rosi S, Ramirez-Amaya V, Vazdarjanova A, Cipriani B, Brosnan CF, Ricciardi-Castagnoli Worley PF, Barnes CA, and Wenk GL. 2005. P, Stern LJ, Strominger JL, and Riese R. Neuroinflammation alters the hippocampal 2001. Developmental plasticity of CNS pattern of behaviorally induced Arc expression. microglia. Proc Natl Acad Sci U S A 98:6295- J Neurosci 25:723-731. 6300. Rosman GJ, Martins TJ, Sonnenburg WK, Beavo Sanz MJ, Cortijo J, and Morcillo EJ. 2005. PDE4 JA, Ferguson K, and Loughney K. 1997. inhibitors as new anti-inflammatory drugs: Isolation and characterization of human effects on cell trafficking and cell adhesion cDNAs encoding a cGMP- stimulated 3',5'- molecules expression. Pharmacol Ther cyclic nucleotide phosphodiesterase. Gene 106:269-297. 191:89-95. Saper CB. 1998. Neurobiological basis of fever. Roth J, Harre EM, Rummel C, Gerstberger R, and Ann N Y Acad Sci 856:90-94. Hubschle T. 2004. Signaling the brain in systemic inflammation: role of sensory Sasaki T, Kotera J, and Omori K. 2002. Novel circumventricular organs. Front Biosci 9:290- alternative splice variants of rat 300. phosphodiesterase 7B showing unique tissue- specific expression and phosphorylation. Rubin LL and Staddon JM. 1999. The cell biology Biochem J 361:211-220. of the blood-brain barrier. Annu Rev Neurosci 22:11-28. Sasaki T, Kotera J, and Omori K. 2004. Transcriptional activation of Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, phosphodiesterase 7B1 by dopamine D1 Tang XB, and Beavo JA. 2003. PDE5 is receptor stimulation through the cyclic converted to an activated state upon cGMP AMP/cyclic AMP-dependent protein binding to the GAF A domain. EMBO J 22:469- kinase/cyclic AMP-response element binding 478. protein pathway in primary striatal neurons. J Sadhu K, Hensley K, Florio VA, and Wolda SL. Neurochem 89:474-483. 1999. Differential expression of the cyclic Sasaki T, Kotera J, Yuasa K, and Omori K. 2000. GMP-stimulated phosphodiesterase PDE2A in Identification of human PDE7B, a cAMP- human venous and capillary endothelial cells. specific phosphodiesterase. Biochem Biophys J Histochem Cytochem 47:895-906. Res Commun 271:575-583. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda Scherbel U, Raghupathi R, Nakamura M, S, and Saito I. 1995. A selective type V Saatman KE, Trojanowski JQ, Neugebauer E, phosphodiesterase inhibitor, E4021, dilates Marino MW, and McIntosh TK. 1999. porcine large coronary artery. J Pharmacol Differential acute and chronic responses of Exp Ther 272:825-831. tumor necrosis factor-deficient mice to experimental brain injury. Proceedings of the 195 Bibliografía National Academy of Sciences of the United Seeger TF, Bartlett B, Coskran TM, Culp JS, States of America 96:8721-8726. James LC, Krull DL, Lanfear J, Ryan AM, Schiltz JC and Sawchenko PE. 2002. Distinct Schmidt CJ, Strick CA, Varghese AH, Williams brain vascular cell types manifest inducible RD, Wylie PG, and Menniti FS. 2003. cyclooxygenase expression as a function of Immunohistochemical localization of PDE10A the strength and nature of immune insults. J in the rat brain. Brain Res 985:113-126. Neurosci 22:5606-5618. Seldon PM, Barnes PJ, Meja K, and Giembycz Schmidt HH, Gagne GD, Nakane M, Pollock JS, MA. 1995. Suppression of lipopolysaccharide- Miller MF, and Murad F. 1992. Mapping of induced tumor necrosis factor-alpha neural nitric oxide synthase in the rat suggests generation from human peripheral blood frequent co-localization with NADPH monocytes by inhibitors of phosphodiesterase diaphorase but not with soluble guanylyl 4: interaction with stimulants of adenylyl cyclase, and novel paraneural functions for cyclase. Mol Pharmacol 48:747-757. nitrinergic signal transduction. J Histochem Selkoe DJ. 1991. The molecular pathology of Cytochem 40:1439-1456. Alzheimer's disease. Neuron 6:487-498. Schmidt K, Schrammel A, Koesling D, and Mayer Selkoe DJ. 2004. Alzheimer disease: mechanistic B. 2001. Molecular mechanisms involved in understanding predicts novel therapies. Ann the synergistic activation of soluble guanylyl Intern Med 140:627-638. cyclase by YC-1 and nitric oxide in endothelial Sette C and Conti M. 1996. Phosphorylation and cells. Mol Pharmacol 59:220-224. activation of a cAMP-specific Schneider HH, Schmiechen R, Brezinski M, and phosphodiesterase by the cAMP-dependent Seidler J. 1986. Stereospecific binding of the protein kinase. Involvement of serine 54 in the antidepressant rolipram to brain protein enzyme activation. J Biol Chem 271:16526- structures. Eur J Pharmacol 127:105-115. 16534. Schnell L, Fearn S, Klassen H, Schwab ME, and Sette C, Iona S, and Conti M. 1994. The short- Perry VH. 1999a. Acute inflammatory term activation of a rolipram-sensitive, cAMP- responses to mechanical lesions in the CNS: specific phosphodiesterase by thyroid- differences between brain and spinal cord. Eur stimulating hormone in thyroid FRTL-5 cells is J Neurosci 11:3648-3658. mediated by a cAMP-dependent Schnell L, Fearn S, Schwab ME, Perry VH, and phosphorylation. J Biol Chem 269:9245-9252. Anthony DC. 1999b. Cytokine-induced acute Shabb JB, Ng L, and Corbin JD. 1990. One inflammation in the brain and spinal cord. J Amino-Acid Change Produces A High-Affinity Neuropathol Exp Neurol 58:245-254. Cgmp-Binding Site in Camp-Dependent Schulz M and Engelhardt B. 2005. The Protein-Kinase. Journal of Biological circumventricular organs participate in the Chemistry 265:16031-16034. immunopathogenesis of experimental Shakur Y, Pryde JG, and Houslay MD. 1993. autoimmune encephalomyelitis. Cerebrospinal Engineered deletion of the unique N-terminal Fluid Res 2:8. domain of the cyclic AMP- specific Schulz S, Yuen PS, and Garbers DL. 1991. The phosphodiesterase RD1 prevents plasma expanding family of guanylyl cyclases. Trends membrane association and the attainment of Pharmacol Sci 12:116-120. enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem J Schwabe U, Miyake M, Ohga Y, and Daly JW. 292 ( Pt 3):677-686. 1976. 4-(3-Cyclopentyloxy-4-methoxyphenyl)- 2-pyrrolidone (ZK 62711): a potent inhibitor of Shaw JA, Perry VH, and Mellanby J. 1990. adenosine cyclic 3',5'-monophosphate Tetanus toxin-induced seizures cause phosphodiesterases in homogenates and microglial activation in rat hippocampus. tissue slices from rat brain. Mol Pharmacol Neurosci Lett 120:66-69. 12:900-910. Shepherd M, McSorley T, Olsen AE, Johnston LA, Scotland G, Beard M, Erdogan S, Huston E, Thomson NC, Baillie GS, Houslay MD, and McCallum F, MacKenzie SJ, Peden AH, Bolger GB. 2003. Molecular cloning and Pooley L, Rena NG, Ross AH, Yarwood SJ, subcellular distribution of the novel PDE4B4 and Houslay MD. 1998. Intracellular cAMP-specific phosphodiesterase isoform. compartmentalization of PDE4 cyclic AMP- Biochem J 370:429-438. specific phosphodiesterases. Methods 14:65- Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, 79. Feil R, Wolfsgruber W, Hofmann F, and Beavo Scott AI, Perini AF, Shering PA, and Whalley LJ. JA. 2003. Individual cerebellar Purkinje cells 1991. In-patient major depression: is rolipram express different cGMP phosphodiesterases as effective as amitriptyline? Eur J Clin (PDEs): in vivo phosphorylation of cGMP- Pharmacol 40:127-129. specific PDE (PDE5) as an indicator of cGMP- dependent protein kinase (PKG) activation. J Scott JD. 1991. Cyclic nucleotide-dependent Neurosci 23:6452-6459. protein kinases. Pharmacol Ther 50:123-145. Shitsukawa K, Andersen CB, Richard FJ, Horner Scott PH and Lawrence JCJ. 1998. Attenuation of AK, Wiersma A, van Duin M, and Conti M. mammalian target of rapamycin activity by 2001. Cloning and characterization of the increased cAMP in 3T3-L1 adipocytes. J Biol cyclic guanosine monophosphate-inhibited Chem 273:34496-34501. phosphodiesterase PDE3A expressed in mouse oocyte. Biol Reprod 65:188-196. 196 Bibliografía Shrikant P and Benveniste EN. 1996. The central Quantitative analysis of inflammatory cells in nervous system as an immunocompetent situ. J Immunol 132:2393-2401. organ: role of glial cells in antigen Soderling SH, Bayuga SJ, and Beavo JA. 1998a. presentation. J Immunol 157:1819-1822. Cloning and characterization of a cAMP- Silva AJ. 2003. Molecular and cellular cognitive specific cyclic nucleotide phosphodiesterase. studies of the role of synaptic plasticity in Proc Natl Acad Sci U S A 95:8991-8996. memory. J Neurobiol 54:224-237. Soderling SH, Bayuga SJ, and Beavo JA. 1998b. Silva AJ, Kogan JH, Frankland PW, and Kida S. Identification and characterization of a novel 1998. CREB and memory. Annu Rev Neurosci family of cyclic nucleotide phosphodiesterases. 21:127-148. J Biol Chem 273:15553-15558. Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Soderling SH, Bayuga SJ, and Beavo JA. 1999. Kostovic I, Winblad B, and Bogdanovic N. Isolation and characterization of a dual- 2000. nNOS expression in reactive astrocytes substrate phosphodiesterase gene family: correlates with increased cell death related PDE10A. Proc Natl Acad Sci U S A 96:7071- DNA damage in the hippocampus and 7076. entorhinal cortex in Alzheimer's disease. Soderling SH and Beavo JA. 2000. Regulation of Experimental Neurology 165:12-26. cAMP and cGMP signaling: new Simons K and Ikonen E. 1997. Functional rafts in phosphodiesterases and new functions. Curr cell membranes. Nature 387:569-572. Opin Cell Biol 12:174-179. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara Sommer N, Loschmann PA, Northoff GH, Weller RA, James LC, Williams RD, Stock JL, M, Steinbrecher A, Steinbach JP, Lichtenfels McNeish JD, Strick CA, Menniti FS, and R, Meyermann R, Riethmuller A, Fontana A, Schmidt CJ. 2006. Genetic deletion of the Dighgans J, Martin R, and . 1995. The striatum-enriched phosphodiesterase antidepressant rolipram suppresses cytokine PDE10A: Evidence for altered striatal function. production and prevents autoimmune Neuropharmacology 51:374-385. encephalomyelitis. Nat Med 1:244-248. Skalhegg BS, Landmark BF, Doskeland SO, Sommer N, Martin R, McFarland HF, Quigley L, Hansson V, Lea T, and Jahnsen T. 1992. Cannella B, Raine CS, Scott DE, Loschmann Cyclic AMP-dependent protein kinase type I PA, and Racke MK. 1997. Therapeutic mediates the inhibitory effects of 3',5'-cyclic potential of phosphodiesterase type 4 adenosine monophosphate on cell replication inhibition in chronic autoimmune demyelinating in human T lymphocytes. J Biol Chem disease. J Neuroimmunol 79:54-61. 267:15707-15714. Sospedra M and Martin R. 2005. Immunology of Smith CJ, Huang R, Sun D, Ricketts S, Hoegler C, multiple sclerosis. Annu Rev Immunol 23:683- Ding JZ, Moggio RA, and Hintze TH. 1997. 747. Development of decompensated dilated Souness JE, Aldous D, and Sargent C. 2000a. cardiomyopathy is associated with decreased Immunosuppressive and anti-inflammatory gene expression and activity of the - effects of cyclic AMP phosphodiesterase sensitive cAMP phosphodiesterase PDE3A. (PDE) type 4 inhibitors. Immunopharmacology Circulation 96:3116-3123. 47:127-162. Smith KJ, Scotland G, Beattie J, Trayer IP, and Souness JE, Aldous D, and Sargent C. 2000b. Houslay MD. 1996. Determination of the Immunosuppressive and anti-inflammatory structure of the N-terminal splice region of the effects of cyclic AMP phosphodiesterase cyclic AMP-specific phosphodiesterase RD1 (PDE) type 4 inhibitors. Immunopharmacology (RNPDE4A1) by 1H NMR and identification of 47:127-162. the membrane association domain using chimeric constructs. J Biol Chem 271:16703- Souness JE and Rao S. 1997. Proposal for 16711. pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal Smith SJ, Brookes-Fazakerley S, Donnelly LE, 9:227-236. Barnes PJ, Barnette MS, and Giembycz MA. 2003. Ubiquitous expression of Southam E and Garthwaite J. 1993. The nitric phosphodiesterase 7A in human oxide-cyclic GMP signalling pathway in rat proinflammatory and immune cells. Am J brain. Neuropharmacology 32:1267-1277. Physiol Lung Cell Mol Physiol 284:L279-L289. Spina D. 2003. Phosphodiesterase-4 inhibitors in Smith SJ, Cieslinski LB, Newton R, Donnelly LE, the treatment of inflammatory lung disease. Fenwick PS, Nicholson AG, Barnes PJ, Drugs 63:2575-2594. Barnette MS, and Giembycz MA. 2004. Springer TA. 1994. Traffic signals for lymphocyte Discovery of BRL 50481 [3-(N,N- recirculation and leukocyte emigration: the dimethylsulfonamido)-4-methyl-nitrobenzene], multistep paradigm. Cell 76:301-314. a selective inhibitor of phosphodiesterase 7: in Stacey P, Rulten S, Dapling A, and Phillips SC. vitro studies in human monocytes, lung 1998. Molecular cloning and expression of macrophages, and CD8+ T-lymphocytes. Mol human cGMP-binding cGMP-specific Pharmacol 66:1679-1689. phosphodiesterase (PDE5). Biochem Biophys Sobel RA, Blanchette BW, Bhan AK, and Colvin Res Commun 247:249-254. RB. 1984. The immunopathology of Stasch JP, Becker EM, Alonso-Alija C, Apeler H, experimental allergic encephalomyelitis. I. Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder 197 Bibliografía W, Stahl E, Steinke W, Straub A, and adenylyl cyclases. Annu Rev Pharmacol Schramm M. 2001. NO-independent regulatory Toxicol 36:461-480. site on soluble guanylate cyclase. Nature Sundkvist E, Jaeger R, and Sager G. 2002. 410:212-215. Pharmacological characterization of the ATP- Steele MR, McCahill A, Thompson DS, dependent low K-m guanosine 3 ',5 '-cyclic MacKenzie C, Isaacs NW, Houslay MD, and monophosphate (cGMP) transporter in human Bolger GB. 2001. Identification of a surface on erythrocytes. Biochemical Pharmacology the beta-propeller protein RACK1 that interacts 63:945-949. with the cAMP-specific phosphodiesterase Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, PDE4D5. Cell Signal 13:507-513. Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Stein CA. 2001. The experimental use of Eum SJ, Park SY, Lee JO, Lee TG, Ro S, and antisense oligonucleotides: a guide for the Cho JM. 2003. Structure of the catalytic perplexed. Journal of Clinical Investigation domain of human phosphodiesterase 5 with 108:641-644. bound drug molecules. Nature 425:98-102. Steiner AA, Ivanov AI, Serrats J, Hosokawa H, Sutherland EW and Rall TW. 1958. Fractionation Phayre AN, Robbins JR, Roberts JL, and characterization of a cyclic adenine Kobayashi S, Matsumura K, Sawchenko PE, ribonucleotide formed by tissue particles. J and Romanovsky AA. 2006. Cellular and Biol Chem 232:1077-1091. molecular bases of the initiation of Fever. Suttorp N, Ehreiser P, Hippenstiel S, Fuhrmann PLoS Biol 4:e284. M, Krull M, Tenor H, and Schudt C. 1996a. Steiner MK, Preston IR, Klinger JR, and Hill NS. Hyperpermeability of pulmonary endothelial 2005. Pulmonary hypertension: inhaled nitric monolayer: Protective role of oxide, sildenafil and natriuretic peptides. Curr phosphodiesterase isoenzymes 3 and 4. Lung Opin Pharmacol 5:245-250. 174:181-194. Steinman L. 1993. Autoimmune disease. Sci Am Suttorp N, Hippenstiel S, Fuhrmann M, Krull M, 269:106-114. and Podzuweit T. 1996b. Role of nitric oxide Steinman L and Zamvil SS. 2006. How to and phosphodiesterase isoenzyme II for successfully apply animal studies in reduction of endothelial hyperpermeability. experimental allergic encephalomyelitis to American Journal of Physiology-Cell research on multiple sclerosis. Annals of Physiology 39:C778-C785. Neurology 60:12-21. Suttorp N, Weber U, Welsch T, and Schudt C. Stern EL, Quan N, Proescholdt MG, and 1993. Role of phosphodiesterases in the Herkenham M. 2000. Spatiotemporal induction regulation of endothelial permeability in vitro. J patterns of cytokine and related immune signal Clin Invest 91:1421-1428. molecule mRNAs in response to intrastriatal Swinnen JV, Joseph DR, and Conti M. 1989a. injection of lipopolysaccharide. J Molecular cloning of rat homologues of the Neuroimmunol 109:245-260. Drosophila melanogaster dunce cAMP Streit WJ. 2004. Microglia and Alzheimer's phosphodiesterase: evidence for a family of disease pathogenesis. J Neurosci Res 77:1-8. genes. Proc Natl Acad Sci U S A 86:5325- 5329. Streit WJ and Kincaid-Colton CA. 1995. The brain's immune system. Sci Am 273:54-61. Swinnen JV, Joseph DR, and Conti M. 1989b. The mRNA encoding a high-affinity cAMP Stryer L. 1996. Vision: from photon to perception. phosphodiesterase is regulated by hormones Proc Natl Acad Sci U S A 93:557-559. and cAMP. Proc Natl Acad Sci U S A 86:8197- Sudo T, Tachibana K, Toga K, Tochizawa S, 8201. Inoue Y, Kimura Y, and Hidaka H. 2000. Szabo C. 1996. Physiological and Potent effects of novel anti-platelet pathophysiological roles of nitric oxide in the aggregatory analogues on central nervous system. Brain Res Bull recombinant cyclic nucleotide 41:131-141. phosphodiesterase isozyme activity. Biochem Pharmacol 59:347-356. Szpirer C, Szpirer J, Riviere M, Swinnen J, Vicini E, and Conti M. 1995. Chromosomal Sullivan M, Olsen AS, and Houslay MD. 1999. localization of the human and rat genes Genomic organisation of the human cyclic (PDE4D and PDE4B) encoding the cAMP- AMP-specific phosphodiesterase PDE4C gene specific phosphodiesterases 3 and 4. and its chromosomal localisation to 19p13.1, Cytogenet Cell Genet 69:11-14. between RAB3A and JUND. Cell Signal 11:735-742. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, and Duman RS. 1999. Chronic Sullivan M, Rena G, Begg F, Gordon L, Olsen AS, antidepressant administration increases the and Houslay MD. 1998. Identification and expression of cAMP- specific characterization of the human homologue of phosphodiesterase 4A and 4B isoforms. J the short PDE4A cAMP-specific Neurosci 19:610-618. phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at Takahashi M and Tokuyama S. 1998. chromosome 19p13.2. Biochem J 333 ( Pt Pharmacological and physiological effects of 3):693-703. ginseng on actions induced by opioids and psychostimulants. Methods Find Exp Clin Sunahara RK, Dessauer CW, and Gilman AG. Pharmacol 20:77-84. 1996. Complexity and diversity of mammalian

198 Bibliografía Takahashi N, Tetsuka T, Uranishi H, and Binding Phosphodiesterase by Cgmp. Journal Okamoto T. 2002. Inhibition of the NF-kappaB of Biological Chemistry 265:14971-14978. transcriptional activity by protein kinase A. Eur Thomas WE. 1992. Brain macrophages: J Biochem 269:4559-4565. evaluation of microglia and their functions. Takimoto E, Champion HC, Belardi D, Moslehi J, Brain Res Brain Res Rev 17:61-74. Mongillo M, Mergia E, Montrose DC, Isoda T, Thomas WE. 1999. Brain macrophages: on the Aufiero K, Zaccolo M, Dostmann WR, Smith role of pericytes and perivascular cells. Brain CJ, and Kass DA. 2005. cGMP catabolism by Res Brain Res Rev 31:42-57. phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent Thompson WJ and Appleman MM. 1971. Multiple mechanism. Circulation Research 96:100-109. cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10:311-316. Takuma K, Phuagphong P, Lee E, Mori K, Baba A, and Matsuda T. 2001. Anti-apoptotic effect Torras-Llort M and Azorin F. 2003. Functional of cGMP in cultured astrocytes: inhibition by characterization of the human cGMP-dependent protein kinase of phosphodiesterase 7A1 promoter. Biochem J mitochondrial permeable transition pore. J Biol 373:835-843. Chem 276:48093-48099. Tremblay J, Desjardins R, Hum D, Gutkowska J, Tang Y, Osawa H, Onuma H, Nishimiya T, Ochi and Hamet P. 2002. Biochemistry and M, Sugita A, and Makino H. 2001. physiology of the natriuretic peptide receptor Phosphodiesterase 3B gene expression is guanylyl cyclases. Molecular and Cellular enhanced in the liver but reduced in the Biochemistry 230:31-47. adipose tissue of obese insulin resistant db/db Tully T, Bourtchouladze R, Scott R, and Tallman mouse. Diabetes Res Clin Pract 54:145-155. J. 2003. Targeting the CREB pathway for Tariot PN, Farlow MR, Grossberg GT, Graham memory enhancers. Nat Rev Drug Discov SM, McDonald S, and Gergel I. 2004. 2:267-277. Memantine treatment in patients with Tuohy VK, Lu Z, Sobel RA, Laursen RA, and Lees moderate to severe Alzheimer disease already MB. 1989. Identification of an encephalitogenic receiving donepezil: a randomized controlled determinant of myelin proteolipid protein for trial. JAMA 291:317-324. SJL mice. J Immunol 142:1523-1527. Tasken K and Aandahl EM. 2004. Localized Turowski P, Adamson P, and Greenwood J. 2005. effects of cAMP mediated by distinct routes of Pharmacological targeting of ICAM-1 signaling protein kinase A. Physiol Rev 84:137-167. in brain endothelial cells: potential for treating Tasken K and Stokka AJ. 2006. The molecular neuroinflammation. Cell Mol Neurobiol 25:153- machinery for cAMP-dependent 170. immunomodulation in T-cells. Biochem Soc Turrin NP, Gayle D, Ilyin SE, Flynn MC, Langhans Trans 34:476-479. W, Schwartz GJ, and Plata-Salaman CR. Tasken KA, Collas P, Kemmner WA, Witczak O, 2001. Pro-inflammatory and anti-inflammatory Conti M, and Tasken K. 2001. cytokine mRNA induction in the periphery and Phosphodiesterase 4D and protein kinase a brain following intraperitoneal administration of type II constitute a signaling unit in the bacterial lipopolysaccharide. Brain Res Bull centrosomal area. J Biol Chem 276:21999- 54:443-453. 22002. Ubogu EE, Cossoy MB, and Ransohoff RM. 2006. Tcheudji JFK, Lebeau L, Virmaux N, Maftei CG, The expression and function of chemokines Cote RH, Lugnier C, and Schultz P. 2001. involved in CNS inflammation. Trends Molecular organization of bovine rod cGMP- Pharmacol Sci 27:48-55. phosphodiesterase 6. Journal of Molecular Ueda N, Iniguez-Lluhi JA, Lee E, Smrcka AV, Biology 310:781-791. Robishaw JD, and Gilman AG. 1994. G protein Teixeira MM, Gristwood RW, Cooper N, and beta gamma subunits. Simplified purification Hellewell PG. 1997. Phosphodiesterase and properties of novel isoforms. J Biol Chem (PDE)4 inhibitors: anti-inflammatory drugs of 269:4388-4395. the future? Trends Pharmacol Sci 18:164-171. Ulvestad E, Williams K, Bjerkvig R, Tiekotter K, Terayama R, Bando Y, Yamada M, and Yoshida Antel J, and Matre R. 1994. Human microglial S. 2005. Involvement of neuropsin in the cells have phenotypic and functional pathogenesis of experimental autoimmune characteristics in common with both encephalomyelitis. Glia 52:108-118. macrophages and dendritic antigen-presenting cells. J Leukoc Biol 56:732-740. Terry R, Cheung YF, Praestegaard M, Baillie GS, Huston E, Gall I, Adams DR, and Houslay MD. Vallar L, Spada A, and Giannattasio G. 1987. 2003. Occupancy of the catalytic site of the Altered Gs and Adenylate-Cyclase Activity in PDE4A4 cyclic AMP phosphodiesterase by Human Gh-Secreting Pituitary-Adenomas. rolipram triggers the dynamic redistribution of Nature 330:566-569. this specific isoform in living cells through a van Staveren WC, Glick J, Markerink-Van Ittersum cyclic AMP independent process. Cell Signal M, Shimizu M, Beavo JA, Steinbusch HW, and 15:955-971. de Vente J. 2002. Cloning and localization of Thomas MK, Francis SH, and Corbin JD. 1990. the cGMP-specific phosphodiesterase type 9 Substrate-Directed and Kinase-Directed in the rat brain. J Neurocytol 31:729-741. Regulation of Phosphorylation of A Cgmp- van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, 199 Bibliografía Omori K, Beavo JA, and de Vente J. 2003. phosphodiesterase splice variant (PDE9A5). mRNA expression patterns of the cGMP- Differential tissue distribution and subcellular hydrolyzing phosphodiesterases types 2, 5, localization of PDE9A variants. Gene 314:15- and 9 during development of the rat brain. J 27. Comp Neurol 467:566-580. Wang P, Wu P, Ohleth KM, Egan RW, and Billah Vasta V, Shimizu-Albergine M, and Beavo JA. MM. 1999. Phosphodiesterase 4B2 is the 2006. Modulation of Leydig cell function by predominant phosphodiesterase species and cyclic nucleotide phosphodiesterase 8A. Proc undergoes differential regulation of gene Natl Acad Sci U S A 103:19925-19930. expression in human monocytes and Verde I, Pahlke G, Salanova M, Zhang G, Wang neutrophils. Mol Pharmacol 56:170-174. S, Coletti D, Onuffer J, Jin SL, and Conti M. Wayman C, Phillips S, Lunny C, Webb T, Fawcett 2001. Myomegalin is a novel protein of the L, Baxendale R, and Burgess G. 2005. golgi/centrosome that interacts with a cyclic Phosphodiesterase 11 (PDE11) regulation of nucleotide phosphodiesterase. J Biol Chem spermatozoa physiology. Int J Impot Res 276:11189-11198. 17:216-223. Vicini E and Conti M. 1997. Characterization of an Weber IT, Shabb JB, and Corbin JD. 1989. intronic promoter of a cyclic adenosine 3',5'- Predicted Structures of the Cgmp Binding monophosphate (cAMP)-specific Domains of the Cgmp-Dependent Protein- phosphodiesterase gene that confers hormone Kinase - A Key Alanine Threonine Difference and cAMP inducibility. Mol Endocrinol 11:839- in Evolutionary Divergence of Camp and 850. Cgmp Binding-Sites. Biochemistry 28:6122- Vignola AM. 2004. PDE4 inhibitors in COPD--a 6127. more selective approach to treatment. Respir Wedel BJ and Garbers DL. 2001. The guanylyl Med 98:495-503. cyclase family at Y2K. Annual Review of Vilaró MT, Wiederhold KH, Palacios JM, and Physiology 63:215-233. Mengod G. 1992. Muscarinic M2-selective Weeks JL, Zoraghi R, Beasley A, Sekhar KR, ligands also recognize M4 receptors in the rat Francis SH, and Corbin JD. 2005. High brain: evidence from combined in situ biochemical selectivity of , sildenafil hybridization and receptor autoradiography. and vardenafil for human phosphodiesterase Synapse 11:171-183. 5A1 (PDE5) over PDE11A4 suggests the Villoslada P, Hauser SL, Bartke I, Unger J, Heald absence of PDE11A4 cross-reaction in N, Rosenberg D, Cheung SW, Mobley WC, patients. Int J Impot Res 17:5-9. Fisher S, and Genain CP. 2000. Human nerve Wei JY, Roy DS, Leconte L, and Barnstable CJ. growth factor protects common marmosets 1998. Molecular and pharmacological analysis against autoimmune encephalomyelitis by of cyclic nucleotide-gated channel function in switching the balance of T helper cell type 1 the central nervous system. Progress in and 2 cytokines within the central nervous Neurobiology 56:37-64. system. Journal of Experimental Medicine Weiner HL and Frenkel D. 2006. Immunology and 191:1799-1806. immunotherapy of Alzheimer's disease. Nature Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia Reviews Immunology 6:404-416. F, Arancio O, and Shelanski M. 2002. Amyloid Wernet W and Flockerzi V. 1989. Primary beta -peptide inhibition of the PKA/CREB Structure of Mammalian Cgmp-Dependent pathway and long-term potentiation: Protein-Kinase. Biological Chemistry Hoppe- Reversibility by drugs that enhance cAMP Seyler 370:788. signaling. Proc Natl Acad Sci U S A 99:13217- 13221. Wilkie TM, Gilbert DJ, Olsen AS, Chen XN, Amatruda TT, Korenberg JR, Trask BJ, de Wachtel H. 1983. Potential antidepressant activity Jong P, Reed RR, Simon MI, and . 1992. of rolipram and other selective cyclic Evolution of the mammalian G protein alpha adenosine 3',5'-monophosphate subunit multigene family. Nat Genet 1:85-91. phosphodiesterase inhibitors. Neuropharmacology 22:267-272. Wilson M, Sullivan M, Brown N, and Houslay MD. 1994. Purification, characterization and Walsh DA, Perkins JP, and Krebs EG. 1968. An analysis of rolipram inhibition of a human type- adenosine 3',5'-monophosphate-dependant IVA cyclic AMP-specific phosphodiesterase protein kinase from rabbit skeletal muscle. J expressed in yeast. Biochem J 304 ( Pt 2):407- Biol Chem 243:3763-3765. 415. Wang H, Lee Y, and Malbon CC. 2004. PDE6 is Wolfe L, Corbin JD, and Francis SH. 1989. an effector for the Wnt/Ca2+/cGMP-signalling Characterization of A Novel Isozyme of Cgmp- pathway in development. Biochem Soc Trans Dependent Protein-Kinase from Bovine Aorta. 32:792-796. Journal of Biological Chemistry 264:7734- Wang P, Wu P, Egan RW, and Billah MM. 2001. 7741. Human phosphodiesterase 8A splice variants: Wong D, Prameya R, and Dorovini-Zis K. 1999. In cloning, gene organization, and tissue vitro adhesion and migration of T lymphocytes distribution. Gene 280:183-194. across monolayers of human brain Wang P, Wu P, Egan RW, and Billah MM. 2003. microvessel endothelial cells: regulation by Identification and characterization of a new ICAM-1, VCAM-1, E-selectin and PECAM-1. J human type 9 cGMP-specific Neuropathol Exp Neurol 58:138-152.

200 Bibliografía Wunder F, Tersteegen A, Rebmann A, Erb C, F442A preadipocytes requires Janus Fahrig T, and Hendrix M. 2005. kinase/signal transducer and activator of Characterization of the first potent and transcription but not mitogen-activated protein selective PDE9 inhibitor using a cGMP kinase or p70 S6 kinase signaling. J Biol reporter cell line. Mol Pharmacol 68:1775- Chem 274:8662-8668. 1781. Yarwood SJ, Steele MR, Scotland G, Houslay Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, MD, and Bolger GB. 1999b. The RACK1 Kleiman RJ, Morton DG, Stephenson DT, signaling scaffold protein selectively interacts Strick CA, Williams RD, and Menniti FS. 2006. with the cAMP-specific phosphodiesterase Cellular and subcellular localization of PDE4D5 isoform. J Biol Chem 274:14909- PDE10A, a striatum-enriched 14917. phosphodiesterase. Neuroscience 139:597- Yermakova A and O'Banion MK. 2000. 607. Cyclooxygenases in the central nervous Xu RX, Hassell AM, Vanderwall D, Lambert MH, system: implications for treatment of Holmes WD, Luther MA, Rocque WJ, Milburn neurological disorders. Curr Pharm Des MV, Zhao Y, Ke H, and Nolte RT. 2000. 6:1755-1776. Atomic structure of PDE4: insights into Yoshimura M and Tabakoff B. 1999. Ethanol's phosphodiesterase mechanism and specificity. actions on cAMP-mediated signaling in cells Science 288:1822-1825. transfected with type VII adenylyl cyclase. Yamagata K, Matsumura K, Inoue W, Shiraki T, Alcoholism-Clinical and Experimental Suzuki K, Yasuda S, Sugiura H, Cao C, Research 23:1457-1461. Watanabe Y, and Kobayashi S. 2001. Yuasa K, Kanoh Y, Okumura K, and Omori K. Coexpression of microsomal-type 2001a. Genomic organization of the human prostaglandin e synthase with phosphodiesterase PDE11A gene. cyclooxygenase-2 in brain endothelial cells of Evolutionary relatedness with other PDEs rats during endotoxin-induced fever. J containing GAF domains. Eur J Biochem Neurosci 21:2669-2677. 268:168-178. Yamashita N, Hayashi A, Baba J, and Sawa A. Yuasa K, Kotera J, Fujishige K, Michibata H, 1997. Rolipram, a phosphodiesterase-4- Sasaki T, and Omori K. 2000. Isolation and selective inhibitor, promotes the survival of characterization of two novel cultured rat dopaminergic neurons. Jpn J phosphodiesterase PDE11A variants showing Pharmacol 75:155-159. unique structure and tissue-specific Yan C, Bentley JK, Sonnenburg WK, and Beavo expression. J Biol Chem 275:31469-31479. JA. 1994. Differential expression of the 61 kDa Yuasa K, Ohgaru T, Asahina M, and Omori K. and 63 kDa calmodulin-dependent 2001b. Identification of rat cyclic nucleotide phosphodiesterases in the mouse brain. J phosphodiesterase 11A (PDE11A): Neurosci 14:973-984. comparison of rat and human PDE11A splicing Yan C, Zhao AZ, Bentley JK, and Beavo JA. 1996. variants. Eur J Biochem 268:4440-4448. The calmodulin-dependent phosphodiesterase Zeller E, Stief HJ, Pflug B, and Sastre. 1984. gene PDE1C encodes several functionally Results of a phase II study of the different splice variants in a tissue-specific antidepressant effect of rolipram. manner. Journal of Biological Chemistry Pharmacopsychiatry 17:188-190. 271:25699-25706. Zgaljardic DJ, Borod JC, Foldi NS, and Mattis P. Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai 2003. A review of the cognitive and behavioral Y, Michibata H, Fujishige K, Kawai E, sequelae of Parkinson's disease: relationship Takebayashi S, Okumura K, and Omori K. to frontostriatal circuitry. Cogn Behav Neurol 1998. Expression, structure and chromosomal 16:193-210. localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A Zhang B, Yang L, Konishi Y, Maeda N, Sakanaka gene. Eur J Biochem 255:391-399. M, and Tanaka J. 2002a. Suppressive effects of phosphodiesterase type IV inhibitors on rat Yang G and Li L. 2003. In vivo effects of cultured microglial cells: comparison with other phosphodiesterase III inhibitors on glucose types of cAMP-elevating agents. metabolism and insulin sensitivity. J Chin Med Neuropharmacology 42:262-269. Assoc 66:210-216. Zhang H, Huang Y, Jin S, Frith S, Suvarna N, Yang G, McIntyre KW, Townsend RM, Shen HH, Conti M, and O'Donnell J. 2002b. Pitts WJ, Dodd JH, Nadler SG, McKinnon M, Antidepressant-like Profile and Reduced and Watson AJ. 2003. Phosphodiesterase 7A- Sensitivity to Rolipram in Mice Deficient in the deficient mice have functional T cells. J PDE4D Phosphodiesterase Enzyme. Immunol 171:6414-6420. Neuropsychopharmacology 27:587. Yang Q, Paskind M, Bolger G, Thompson WJ, Zhang J and Snyder SH. 1995. Nitric-Oxide in the Repaske DR, Cutler LS, and Epstein PM. Nervous-System. Annual Review of 1994. A novel cyclic GMP stimulated Pharmacology and Toxicology 35:213-233. phosphodiesterase from rat brain. Biochem Biophys Res Commun 205:1850-1858. Zhang Y, Han HY, Elmquist WF, and Miller DW. 2000a. Expression of various multidrug Yarwood SJ, Sale EM, Sale GJ, Houslay MD, resistance-associated protein (MRP) Kilgour E, and Anderson NG. 1999a. Growth hormone-dependent differentiation of 3T3- 201 Bibliografía homologues in brain microvessel endothelial cells. Brain Research 876:148-153. Zhang YH, Lu J, Elmquist JK, and Saper CB. 2000b. Lipopolysaccharide activates specific populations of hypothalamic and brainstem neurons that project to the spinal cord. J Neurosci 20:6578-6586. Zhang YH, Lu J, Elmquist JK, and Saper CB. 2003. Specific roles of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide- induced fever and Fos expression in rat brain. J Comp Neurol 463:3-12. Zhao AZ, Yan C, Sonnenburg WK, and Beavo JA. 1997. Recent advances in the study of Ca2+/CaM-activated phosphodiesterases: expression and physiological functions. Adv Second Messenger Phosphoprotein Res 31:237-251. Zhong Y and Wu CF. 1991. Altered synaptic plasticity in Drosophila memory mutants with a defective cyclic AMP cascade. Science 251:198-201. Zoraghi R, Bessay EP, Corbin JD, and Francis SH. 2005. Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280:12051-12063. Zufall F, Firestein S, and Shepherd GM. 1994. Cyclic Nucleotide-Gated Ion Channels and Sensory Transduction in Olfactory Receptor Neurons. Annual Review of Biophysics and Biomolecular Structure 23:577-607. Zufall F, Shepherd GM, and Barnstable CJ. 1997. Cyclic nucleotide gated channels as regulators of CNS development and plasticity. Current Opinion in Neurobiology 7:404-412.

202

Top View